FOSUN PHARMA
復星医药

上海復星醫藥(集團)股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026

The Board of the Company is pleased to announce the unaudited interim results of the Group for the six months ended 30 June 2026.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the six months ended 30 June 2026

		For the six months ended 30 June	
		2026	2025
	Notes	***RMB'000***	*RMB'000*
		(Unaudited)	(Unaudited)
REVENUE	*3*	**20,376,519**	19,425,533
Cost of sales		**(10,288,189)**	(10,123,465)
Gross profit		**10,088,330**	9,302,068
Other income	*4*	**155,159**	209,546
Selling and distribution expenses		**(4,418,125)**	(4,211,063)
Administrative expenses		**(2,292,876)**	(2,123,958)
Impairment losses on financial assets		**(28,123)**	(28,734)
Research and development expenses		**(2,086,925)**	(1,716,662)
Other gains	*5*	**633,104**	1,164,076
Other expenses		**(127,165)**	(317,127)
Interest income		**135,224**	163,453
Finance costs	*6*	**(607,386)**	(652,779)
Share of profits and losses of:			
Joint ventures		**(8,208)**	(4,478)
Associates		**1,143,562**	934,139
PROFIT BEFORE TAX	*7*	**2,586,571**	2,718,481
Income tax expense	*8*	**(437,643)**	(618,271)
PROFIT FOR THE PERIOD		**2,148,928**	2,100,210
Attributable to:			
Owners of the parent		**1,721,468**	1,701,967
Non-controlling interests		**427,460**	398,243
		2,148,928	2,100,210
Earnings per share attributable to ordinary equity holders of the parent:	*10*		
Basic and Diluted			
– For profit for the period		**RMB0.65**	RMB0.64

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the six months ended 30 June 2026

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
PROFIT FOR THE PERIOD	**2,148,928**	2,100,210
OTHER COMPREHENSIVE INCOME		
Other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of foreign operations	**(868,563)**	55,886
Share of other comprehensive income of joint ventures	**360**	–
Share of other comprehensive loss of associates	**(40,482)**	(89,946)
Net other comprehensive loss that may be reclassified to profit or loss in subsequent periods	**(908,685)**	(34,060)
Other comprehensive (loss)/income that will not be reclassified to profit or loss in subsequent periods:		
Equity investments designated at fair value through other comprehensive (loss)/income:		
Changes in fair value	**(5,883)**	1,648
Income tax effect	**883**	(247)
Net other comprehensive (loss)/income that will not be reclassified to profit or loss in subsequent periods	**(5,000)**	1,401
OTHER COMPREHENSIVE LOSS FOR THE PERIOD, NET OF TAX	**(913,685)**	(32,659)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	**1,235,243**	2,067,551
Attributable to:		
Owners of the parent	**1,093,502**	1,659,858
Non-controlling interests	**141,741**	407,693
	1,235,243	2,067,551

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

30 June 2026

	Notes	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
NON-CURRENT ASSETS			
Property, plant and equipment		**22,768,197**	22,680,932
Right-of-use assets		**4,967,072**	5,073,385
Goodwill		**10,709,070**	10,809,757
Other intangible assets		**19,917,678**	17,921,184
Investments in joint ventures		**531,225**	441,535
Investments in associates		**27,951,933**	25,891,713
Equity investments designated at fair value through other comprehensive income		**13,335**	19,218
Financial assets at fair value through profit or loss		**828,346**	878,424
Deferred tax assets		**948,694**	985,337
Trade receivables-non-current		**256,786**	213,539
Other non-current assets		**1,697,841**	1,279,896
Total non-current assets		**90,590,177**	86,194,920
CURRENT ASSETS			
Inventories		**5,969,033**	6,252,472
Trade and bills receivables	*11*	**9,686,780**	9,426,890
Contract assets		**140,569**	116,368
Prepayments, other receivables and other assets		**2,686,788**	2,255,295
Financial assets at fair value through profit or loss		**2,430,683**	2,253,870
Debt investments at fair value through other comprehensive income		**266,847**	411,548
Cash and bank balances		**13,618,648**	13,104,229
Total current assets		**34,799,348**	33,820,672
CURRENT LIABILITIES			
Trade and bills payables	*12*	**5,024,757**	5,144,014
Other payables and accruals		**9,187,272**	8,285,398
Interest-bearing bank and other borrowings		**22,776,754**	21,092,321
Lease liabilities		**360,915**	348,401
Contract liabilities		**989,557**	1,299,979
Tax payable		**256,671**	254,204
Total current liabilities		**38,595,926**	36,424,317
NET CURRENT LIABILITIES		**(3,796,578)**	(2,603,645)
TOTAL ASSETS LESS CURRENT LIABILITIES		**86,793,599**	83,591,275

	30 June 2026 *RMB'000* (Unaudited)	31 December 2025 *RMB'000* (Audited)
NON-CURRENT LIABILITIES		
Interest-bearing bank and other borrowings	**13,016,824**	11,861,991
Lease liabilities	**2,877,716**	3,050,770
Deferred tax liabilities	**3,217,275**	3,259,806
Contract liabilities	**1,180,692**	1,089,039
Deferred income	**612,159**	653,383
Other long-term liabilities	**2,525,388**	1,874,312
Total non-current liabilities	**23,430,054**	21,789,301
Net assets	**63,363,545**	61,801,974
EQUITY		
Equity attributable to owners of the parent		
Share capital	**2,670,429**	2,670,429
Treasury shares	**(607,963)**	(607,963)
Reserves	**46,630,351**	46,640,666
	48,692,817	48,703,132
Non-controlling interests	**14,670,728**	13,098,842
Total equity	**63,363,545**	61,801,974

1.1 BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended 30 June 2026 has been prepared in accordance with HKAS 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2025.

As of 30 June 2026, the Group's current assets were RMB34,799,348,000 and current liabilities were RMB38,595,926,000. The financial statements of the Group are prepared based on the basic accounting assumption of going concern. Having taken into account the expected cash flows from operating activities and the unused banking facilities, it will enable the Group to fulfil its maturing debts. Therefore, the Group has adequate working capital in the foreseeable future to meet the needs of its daily operations and will not face any issues related to going concern due to a shortage of working capital.

The financial information relating to the year ended 31 December 2025 that is included in the interim condensed consolidated statements of financial position as comparative information does not constitute the Company's consolidated financial statements for that year but is derived from those financial statements. Further information relating to those statutory financial statements required to be disclosed in accordance with section 436 of the Hong Kong Companies Ordinance is as follows:

The Company has delivered the financial statements for the year ended 31 December 2025 to the Companies Registry (Hong Kong) as required by section 662(3) of, and Part 3 of Schedule 6 to, the Hong Kong Companies Ordinance. The Company's auditors have reported on the financial statements for the year ended 31 December 2025. The auditor's report was unqualified; and did not contain a statement under sections 406(2), 407(2) or 407(3) of the Hong Kong Companies Ordinance.

1.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2025, except for the adoption of the following amended HKFRS Accounting Standards for the first time for the current period's financial information.

Amendments to HKFRS 9 and HKFRS 7	*Amendments to the Classification and Measurement of Financial Instruments*
Amendments to HKFRS 9 and HKFRS 7	*Contracts Referencing Nature-dependent Electricity*
Annual Improvements to HKFRS Accounting Standards – Volume 11	*Amendments to HKFRS 1, HKFRS 7, HKFRS 9, HKFRS 10 and HKAS 7*

The nature and impact of the amended HKFRS Accounting Standards are described below:

(a) Amendments to HKFRS 9 and HKFRS 7 Amendments to the Classification and Measurement of Financial Instruments clarify that a financial asset is derecognised when the entity's rights to the contractual cash flows expire or are transferred, while a financial liability is derecognised on the settlement date. The amendments introduce an accounting policy option to derecognise a financial liability that is settled through an electronic payment system before the settlement date if specified criteria are met. The amendments clarify how to assess the contractual cash flow characteristics of financial assets with environmental, social and governance and other similar contingent features. Moreover, the amendments clarify the requirements for classifying financial assets with non-recourse features and contractually linked instruments. The amendments also include additional disclosures for investments in equity instruments designated at fair value through other comprehensive income and financial instruments with contingent features. Since the Group's accounting policy for the derecognition of financial assets and liabilities in prior years aligned with the amendments and the Group did not have the financial assets that were addressed by the amendments, the amendments did not have any significant impact on the interim condensed consolidated financial information. The Group will provide additional disclosures for its equity investments designated at fair value through other comprehensive income in the Group's consolidated financial statements for the year ending 31 December 2026.

(b) Amendments to HKFRS 9 and HKFRS 7 Contracts Referencing Nature-dependent Electricity clarify the application of the "own-use" requirements for in-scope contracts and amend the designation requirements for a hedged item in a cash flow hedging relationship for in-scope contracts. The amendments also include additional disclosures that enable users of financial statements to understand the effects these contracts have on an entity's financial performance and future cash flows. As the Group did not have any contracts that are in the scope of the amendments, the amendments did not have any significant impact on the interim condensed consolidated financial information.

(c) Annual Improvements to HKFRS Accounting Standards – Volume 11 set out narrow scope amendments to HKFRS 1, HKFRS 7 (and the accompanying Guidance on implementing HKFRS 7), HKFRS 9, HKFRS 10 and HKAS 7. The amendments include clarifications, simplifications, corrections or changes to improve consistency in the corresponding HKFRS Accounting Standards. The amendments did not have any significant impact on the interim condensed consolidated financial information.

2 OPERATING SEGMENT INFORMATION

For management purposes, the Group is organised into business units based on their products and services and has five reportable operating segments as follows:

(a) the pharmaceutical manufacturing segment mainly engages in the R&D, production and sale of medicine;

(b) the medical devices and medical diagnosis segment mainly engages in the R&D, production and sale of medical devices and diagnostic products;

(c) the healthcare service segment mainly engages in the provision of healthcare service and hospital management;

(d) the pharmaceutical distribution and retail segment mainly engages in distribution and retail of medicine and medical devices;

(e) the other business operations segment comprises businesses other than those mentioned above.

Management monitors the results of the Group's operating segments separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on reportable segment profit or loss, which is a measure of adjusted profit or loss after tax. The adjusted profit or loss after tax is measured consistently with the Group's profit or loss after tax except that fair value gain or loss on financial assets at fair value through profit or loss, as well as head office and investment management entities income and expenses are excluded from such measurement.

Intersegment revenues are eliminated on consolidation. Intersegment sales and transfers are transacted with reference to the selling prices used for sales made to third parties at the then prevailing market prices.

Segment assets exclude financial assets at fair value through profit or loss, equity investments designated at fair value through other comprehensive income and unallocated head office and investment management entities assets as these assets are managed on a group basis.

Segment liabilities exclude interest-bearing bank and other borrowings, interest payable and unallocated head office and investment management entities liabilities as these liabilities are managed on a group basis.

For the six months ended 30 June 2026 (unaudited)

	Pharmaceutical manufacturing *RMB'000*	Medical devices and medical diagnosis *RMB'000*	Healthcare Service *RMB'000*	Pharma-ceutical distribution and retail *RMB'000*	Other business operations *RMB'000*	Eliminations *RMB'000*	Total *RMB'000*
Segment revenue							
Sales to external customers	**14,727,043**	**1,858,518**	**3,734,982**	**–**	**55,976**	**–**	**20,376,519**
Intersegment sales	**42,661**	**51,006**	**7,597**	**–**	**37,278**	**(138,542)**	**–**
Total segment revenue	**14,769,704**	**1,909,524**	**3,742,579**	**–**	**93,254**	**(138,542)**	**20,376,519**
Segment results*	**1,834,207**	**(127,500)**	**(85,602)**	**–**	**(2,528)**	**(45,293)**	**1,573,284**
Other income	**127,663**	**4,126**	**11,314**	**–**	**2,071**	**–**	**145,174**
Other gains	**34,132**	**116,868**	**36,219**	**–**	**7**	**(2,229)**	**184,997**
Interest income	**120,002**	**9,899**	**3,057**	**–**	**36**	**(3,960)**	**129,034**
Finance costs	**(163,134)**	**(32,535)**	**(132,437)**	**–**	**(15,564)**	**24,476**	**(319,194)**
Other expenses	**(53,442)**	**(16,689)**	**(47,560)**	**–**	**9**	**10,099**	**(107,583)**
Share of profits and losses of:							
Joint ventures	**(6,162)**	**–**	**(285)**	**–**	**(1,761)**	**–**	**(8,208)**
Associates	**216,994**	**28,705**	**3,153**	**844,806**	**49,904**	**–**	**1,143,562**
Unallocated other income, interest income, other gains, finance cost, and expenses							**(154,495)**
Profit/(loss) before tax	**2,110,260**	**(17,126)**	**(212,141)**	**844,806**	**32,174**	**(16,907)**	**2,586,571**
Tax	**(412,431)**	**(4,531)**	**5,132**	**–**	**30**	**–**	**(411,800)**
Unallocated tax							**(25,843)**
Profit/(loss) for the period	**1,697,829**	**(21,657)**	**(207,009)**	**844,806**	**32,204**	**(16,907)**	**2,148,928**
Segment assets	**70,478,771**	**10,645,265**	**15,958,942**	**21,856,917**	**5,451,583**	**(3,869,508)**	**120,521,970**
Including:							
Investments in joint ventures	**263,206**	**–**	**3,503**	**–**	**264,516**	**–**	**531,225**
Investments in associates	**946,221**	**1,624,336**	**617,147**	**21,856,917**	**2,907,312**	**–**	**27,951,933**
Unallocated assets							**4,867,555**
Total assets							**125,389,525**
Segment liabilities	**23,657,972**	**2,475,658**	**6,794,240**	**–**	**982,159**	**(13,866,808)**	**20,043,221**
Unallocated liabilities							**41,982,759**
Total liabilities							**62,025,980**
Other segment information							
Depreciation and amortisation	**1,207,075**	**179,992**	**443,371**	**–**	**47,829**	**–**	**1,878,267**
Impairment losses recognised in the statement of profit or loss, net	**(6,824)**	**9,750**	**34,382**	**–**	**802**	**(682)**	**37,428**
Impairment losses recognised in the statement of profit or loss, net (unallocated)							**5,638**
Capital expenditure**	**1,852,586**	**80,050**	**159,001**	**–**	**1,489**	**–**	**2,093,126**

* Segment results are obtained as segment revenue less cost of sales, selling and distribution expenses, administrative expenses and research and development expenses.

** Capital expenditure consists of additions to property, plant and equipment, other intangible assets and prepaid land lease payments included in right-of-use assets (excluding the addition from acquisition of subsidiaries).

For the six months ended 30 June 2025 (unaudited)

	Pharmaceutical manufacturing *RMB'000*	Medical devices and medical diagnosis *RMB'000*	Healthcare Service *RMB'000*	Pharma-ceutical distribution and retail *RMB'000*	Other business operations *RMB'000*	Eliminations *RMB'000*	Total *RMB'000*
Segment revenue							
Sales to external customers	13,817,044	1,953,163	3,588,985	–	66,341	–	19,425,533
Intersegment sales	58,844	11,552	12,096	–	33,891	(116,383)	–
Total segment revenue	13,875,888	1,964,715	3,601,081	–	100,232	(116,383)	19,425,533
Segment results*	1,616,713	(55,722)	(40,150)	–	(12,695)	(54,820)	1,453,326
Other income	152,217	18,685	16,228	–	2,486	–	189,616
Other gains	180,372	38,249	109,584	(75,931)	40	–	252,314
Interest income	116,864	11,170	12,238	–	569	(5,324)	135,517
Finance costs	(126,505)	(28,773)	(139,991)	–	(17,982)	31,696	(281,555)
Other expenses	(658)	(721)	(47,833)	–	(5,496)	674	(54,034)
Share of profits and losses of:							
Joint ventures	11	–	(852)	–	(3,637)	–	(4,478)
Associates	(1,770)	61,479	5,848	878,217	(9,635)	–	934,139
Unallocated other income, interest income, other gains, finance cost, and expenses							93,636
Profit/(loss) before tax	1,937,244	44,367	(84,928)	802,286	(46,350)	(27,774)	2,718,481
Tax	(349,974)	(25,358)	(22,823)	–	(19)	–	(398,174)
Unallocated tax							(220,097)
Profit/(loss) for the period	1,587,270	19,009	(107,751)	802,286	(46,369)	(27,774)	2,100,210
Segment assets	63,183,065	10,438,618	16,155,796	20,643,149	4,752,094	(3,429,247)	111,743,475
Including:							
Investments in joint ventures	5,430	–	4,738	–	24,561	–	34,729
Investments in associates	409,433	1,556,892	629,310	20,643,149	1,863,344	–	25,102,128
Unallocated assets							7,046,086
Total assets							118,789,561
Segment liabilities	22,368,423	2,851,525	6,983,326	–	1,950,046	(13,577,761)	20,575,559
Unallocated liabilities							37,937,269
Total liabilities							58,512,828
Other segment information							
Depreciation and amortisation	1,107,518	166,062	403,503	–	61,808	–	1,738,891
Impairment losses recognised in the statement of profit or loss, net	(913)	15,606	31,626	–	6,353	–	52,672
Impairment losses recognised in the statement of profit or loss, net (unallocated)							40,331
Capital expenditure**	1,428,163	134,121	578,105	–	1,124	–	2,141,513

* Segment results are obtained as segment revenue less cost of sales, selling and distribution expenses, administrative expenses and research and development expenses.

** Capital expenditure consists of additions to property, plant and equipment, other intangible assets and prepaid land lease payments included in right-of-use assets (excluding the addition from acquisition of subsidiaries).

3. REVENUE

An analysis of the Group's revenue is as follows:

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue from contracts with customers	**20,344,242**	19,400,540
Revenue from other sources		
Gross rental income	**32,277**	24,993
Total	**20,376,519**	19,425,533

4. OTHER INCOME

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Dividend income from financial assets at fair value through profit or loss	**22,406**	38,893
Dividend income from equity investments designated at fair value through other comprehensive income	**240**	207
Government grants	**132,513**	170,446
Total	**155,159**	209,546

5. OTHER GAINS

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Fair value gain on financial instruments at fair value through profit or loss	**273,652**	–
Gain on disposal of financial assets at fair value through profit or loss	**201,694**	206,310
Gain on disposal of subsidiaries	**130,016**	92,261
Gain on disposal of associates	**3,595**	852,844
Others	**24,147**	12,661
Total	**633,104**	1,164,076

6. FINANCE COSTS

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Interest on bank loans and other borrowings (excluding lease liabilities)	**547,763**	602,116
Interest on lease liabilities	**68,917**	62,199
Subtotal	**616,680**	664,315
Less: Interest capitalised	**(9,294)**	(11,536)
Total	**607,386**	652,779

7. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after crediting/(charging):

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Cost of inventories sold	**6,811,727**	6,815,493
Cost of services provided	**3,476,462**	3,307,972
Staff costs (including Directors', Supervisors' and Chief Executive's remuneration):		
Salaries and other staff costs	**5,262,728**	4,941,908
Retirement benefits:		
Defined contribution fund	**344,770**	334,172
Accommodation benefits:		
Defined contribution fund	**193,448**	192,602
Share-based payment	**295,361**	14,454
	6,096,307	5,483,136
Research and development costs:		
Current period expenditure excluding amortisation of other intangible assets	**1,951,354**	1,580,054
Less: Government grants released*	**(49,512)**	(21,902)
Lease payments not included in the measurement of lease liabilities	**43,474**	51,247
Depreciation of property, plant and equipment	**954,181**	877,733
Depreciation of right-of-use assets	**245,975**	207,584
Amortisation of other intangible assets	**649,753**	604,189
Provision for impairment of inventories and deferred development costs	**7,991**	20,267
Provision for impairment of items of property, plant and equipment	**–**	3,672
Impairment of financial assets		
Impairment of trade receivables	**28,820**	26,420
Impairment of other receivables	**(697)**	2,314
Impairment of investments in associates	**–**	40,331
Foreign exchange loss, net	**46,949**	124,356
Fair value (gain)/loss on financial instruments at fair value through profit or loss, net	**(273,652)**	48,597
Loss on disposal of items of property, plant and equipment and other intangible assets	**1,509**	3,314
Gain on disposal of interests in associates	**(3,595)**	(852,844)
Gain on disposal of financial assets at fair value through profit or loss	**(201,694)**	(206,310)
Gain on disposal of subsidiaries	**(130,016)**	(92,261)

* The Group received various government grants related to research and development projects. The government grants received have been recorded in other income. Government grants received for which related expenditure has not yet been undertaken are included in deferred income in the consolidated statement of financial position. There are no unfulfilled conditions or contingencies relating to these grants.

8. INCOME TAX

The provision for Chinese Mainland current income tax is based on a statutory rate of 25% of the assessable profits of the Group as determined in accordance with the PRC Corporate Income Tax Law which was approved and became effective on 1 January 2008, except for certain subsidiaries of the Group in Chinese Mainland, which are taxed at preferential rates of 0% to 20%.

Taxes on profits assessable in other regions and countries have been calculated at the tax rates prevailing in the jurisdictions in which the Group operates. Hong Kong profits tax has been provided at the rate of 16.5% on the estimated assessable profits arising in Hong Kong during the period, the first HK$2,000,000 of assessable profits are taxed at 8.25% and the remaining assessable profits are taxed at 16.5%. The provision of current income tax of Alma Lasers Ltd., a subsidiary of the Company incorporated in Israel, enjoyed a preferential effective tax rate of 6% for being a Special Preferred Technological Enterprise ("**SPTE**"). The provision of current tax of Gland Pharma Limited ("**Gland Pharma**"), a subsidiary of the Company incorporated in India, was based on a statutory rate of 25.17%. The provision of current tax of Breas Medical Holdings AB ("**Breas**"), a subsidiary of the Company incorporated in Sweden, is based on a statutory rate of 20.6%. The provision of current tax of Tridem Pharma S.A.S ("**Tridem Pharma**"), a subsidiary of the Company incorporated in France, is based on a statutory rate of 25.83%. The provision of current income tax of Phixen SAS ("**Phixen**"), a subsidiary of the Company incorporated in France, is based on a statutory rate of 25.83%.

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Current	**561,515**	459,215
Deferred	**(123,872)**	159,056
Total	**437,643**	618,271

9. DIVIDENDS

The Board of Directors did not recommend the payment of an interim dividend in respect of the six months period ended 30 June 2026 (for the six months period ended 30 June 2025: Nil).

The proposed final dividend of RMB0.39 (inclusive of tax) per ordinary share for the year ended 31 December 2025 was approved by the Shareholders at the annual general meeting of the Company on 16 June 2026.

10. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings per share amounts is based on the profit for the period attributable to ordinary equity holders of the parent, adjusted to reflect the cash dividends distributed to the share scheme [Note] and the weighted average number of ordinary shares of 2,639,554,073 (for the six months period ended 30 June 2025: 2,666,270,174) outstanding during the period.

The calculation of the diluted earnings per share amounts is based on the profit for the period attributable to ordinary equity holders of the parent. The weighted average number of ordinary shares used in the calculation is the number of ordinary shares outstanding during the period, as used in the basic earnings per share calculation, and the weighted average number of ordinary shares assumed to have been issued at no consideration on the deemed conversion of all dilutive potential ordinary shares into ordinary shares.

Note: The collective term for the 2025 A Share Option Incentive Scheme and 2025 H Share Restricted Share Unit Scheme of the Company, the same below.

The calculations of basic and diluted earnings per share are based on:

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Earnings		
Profit attributable to ordinary equity holders of the parent	**1,721,468**	1,701,967
Less: Cash dividends distributed to the share scheme	**–**	–
Adjusted profit attributable to ordinary equity holders of the parent, used in the basic earnings per share calculation	**1,721,468**	1,701,967
Cash dividends distributed to the share scheme	**–**	–
Total	**1,721,468**	1,701,967

	Number of shares	
	For the six months ended 30 June	
	2026	2025
	(Unaudited)	(Unaudited)
Shares		
Weighted average number of ordinary shares outstanding during the year used in the basic earnings per share calculation	**2,639,554,073**	2,666,270,174
Effect of dilution – weighted average number of ordinary shares:		
– Share scheme	**2,571,870**	–
Total	**2,642,125,943**	2,666,270,174

11. TRADE AND BILLS RECEIVABLES

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Trade receivables	**9,639,862**	9,364,522
Bills receivable	**46,918**	62,368
Total	**9,686,780**	9,426,890

The credit period for trade receivables is generally three months, which may be extended up to six months for major customers. Trade and bills receivables are non-interest-bearing.

An ageing analysis of trade receivables, based on the invoice date and net of loss allowance, as at the respective reporting dates is as follows:

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Within 1 year	**9,493,622**	9,210,099
1 to 2 years	**315,094**	302,540
2 to 3 years	**91,896**	124,161
Over 3 years	**123,941**	106,443
	10,024,553	9,743,243
Less: Loss allowance for impairment	**(384,691)**	(378,721)
Net Carrying Amount	**9,639,862**	9,364,522

12. TRADE AND BILLS PAYABLES

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Trade payables	**4,596,560**	4,856,045
Bills payable	**428,197**	287,969
Total	**5,024,757**	5,144,014

Trade and bills payables are non-interest-bearing. Trade payable are normally settled on a two-month term, and bills payable are normally settled on 90 to 180-day terms.

An aged analysis of the trade payables, based on the invoice date, as at the end of the reporting period is as follows:

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Within 1 year	**4,267,468**	4,487,166
1 to 2 years	**134,386**	216,577
2 to 3 years	**66,963**	69,720
Over 3 years	**127,743**	82,582
Total	**4,596,560**	4,856,045

13. EVENTS AFTER THE REPORTING PERIOD

There have been no significant events since the end of the Reporting Period.

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS REVIEW

The Board's Discussion and Analysis on Operations of the Group for the Reporting Period

During the Reporting Period, facing the dual pressure from product price and exchange rate fluctuations, the Group adhered to an innovation driven and deep globalization strategy, maintaining steady growth in performance. In the first half of 2026, the Group achieved a revenue of RMB20,377 million, representing a period-on-period increase of 4.90%. Excluding the impact of exchange rate fluctuations and calculated on constant exchanges rates, the period-on-period increase was 7.32%. Among which: revenue from Innovative Drugs*Note* increased by 13.84% period-on-period, accounting for 33.35% of the pharmaceutical manufacturing business revenue, representing an increase of 2.12 percentage points compared with the same period of last year; overseas business revenue increased by 16.45% period-on-period, with its proportion of the Group's total revenue increasing to 31.30%, up by 3.11 percentage points compared with the same period of last year.

During the Reporting Period, the revenue structure of the Group was as follows:

Unit: million Currency: RMB

	Revenue Jan-Jun 2026		Revenue Jan-Jun 2025		Period-on-period increase/ decrease
	Amount	**Percentage of revenue**	Amount	Percentage of revenue	
By business segments					
Pharmaceutical manufacturing	**14,727**	**72.27%**	13,817	71.13%	6.59%
Including: revenue from Innovative Drugs	**4,911**	**24.10%**	4,314	22.21%	13.84%
Medical devices and medical diagnosis	**1,859**	**9.12%**	1,953	10.05%	-4.81%
Healthcare services	**3,735**	**18.33%**	3,589	18.48%	4.07%
By geographical locations					
Chinese mainland	**13,998**	**68.70%**	13,948	71.80%	0.36%
Regions outside Chinese mainland and other countries	**6,379**	**31.30%**	5,478	28.20%	16.45%

Note: Innovative Drugs include: Trastuzumab for injection (Brand name in Chinese mainland: Han Qu You) and trastuzumab drug substance, Han Li Kang (rituximab injection), Serplulimab injection (Brand name in Chinese mainland: Han Si Zhuang), Akynzeo (netupitant and palonosetron hydrochloride capsules), Yi Kai Da (ejilunsai injection), Yi Xin Tan (sacubitril valsartan sodium tablets), Han Bei Tai (bevacizumab injection), Han Nai Jia (neratinib maleate tablets), Bei Wen (keverprazan hydrochloride tablets), Pei Jin (telpegfilgrastim injection), Su Ke Xin (avatrombopag maleate tablets), Han Da Yuan (adalimumab injection), Pu Rui Ni (pretomanid tablets), DAXXIFY (botulinum toxin type A for injection), Fu Ke Shu (anti-human T-lymphocyte rabbit immunoglobulin), Fu Mai Ning (luvometinib tablets), Otezla (apremilast tablets), Denosumab Injection, Fu Tuo Ning (fovinaciclib citrate capsules), Han Bei You (pertuzumab injection), Wan Ti Le (tenapanor hydrochloride tablets), Pang Bi Fu (etelcalcetide hydrochloride injection), etc.

I. Main Operational Progress of the Group during the Reporting Period

1. *Being Innovation-driven: Focusing on Core Areas and Continuously Enhancing Global R&D and Transformation Capabilities*

(1) *R&D investment continued to increase with significant innovation transformation progress*

Sustained R&D expenditure intensity: In the first half of 2026, the Group's total R&D expenditure amounted to RMB3,247 million, representing a period-on-period increase of 25.66%; of which R&D expenses amounted to RMB2,087 million, representing a period-on-period increase of 21.55%. Total R&D expenditure in the pharmaceutical manufacturing business amounted to RMB3,046 million, representing a period-on-period increase of 32.72%; of which R&D expenses amounted to RMB1,898 million, representing a period-on-period increase of 29.20%. R&D expenditure related to Innovative Drugs reached RMB2,650 million, representing a period-on-period increase of 48.38%; R&D expenditure in Innovative Drugs accounted for 81.61% of the Group's total R&D expenditure, representing a period-on-period increase of 12.50 percentage points, and accounted for 87.00% of the pharmaceutical manufacturing business's R&D expenditure, representing a period-on-period increase of 9.18 percentage points, and indicating that resources are continuously tilting towards innovative drugs.

– **R&D achievements continued to emerge:**

- Launches and new drug applications of innovative drugs and products: the Group consistently adheres to a clinical value-oriented approach and continually enhances product pipeline quality. During the Reporting Period, a total of 20 indications of 7 Innovative Drugs were approved for launch both domestically and internationally, and the NDA for 4 Innovative Drugs have been accepted.

During the Reporting Period, Fu Mai Ning (luvometinib tablets) was approved for launch in Chinese mainland for the treatment of pediatric and adolescent patients with relapsed or refractory Langerhans cell histiocytosis (LCH), Han Si Zhuang (serplulimab injection) in combination with chemotherapy was approved for launch in Chinese mainland for the neoadjuvant/adjuvant treatment of gastric cancer; marketing authorization applications for three new indications of serplulimab injection were approved by the EC, namely first-line treatment in combination with chemotherapy for squamous non-small cell lung cancer (sqNSCLC), esophageal squamous cell carcinoma (ESCC), and non-squamous non-small cell lung cancer (nsNSCLC); pertuzumab biosimilar was approved for launch in Chinese mainland and the EU, covering all indications that the reference pertuzumab has been approved in these respective local markets; and Fortacin spray (lidocaine and prilocaine aerosol) was approved for launch in Chinese mainland for premature ejaculation.

In addition, new products under the Breas Apto mask series were launched in Europe, and their U.S. regulatory filing process is also progressing steadily.

- Development of generic drugs: during the Reporting Period, a total of over 30 generic drugs varieties were approved for launch both domestically and internationally. Several of these varieties were the first or among the first three generic drugs of their kinds in China, effectively strengthening the market competitiveness of the mature product lines.

- Clinical progress: the R&D pipelines have been advanced efficiently. During the Reporting Period, around 30 clinical trial applications for Innovative Drugs were approved by domestic and overseas regulatory authorities, with multiple core pipelines entering pivotal clinical stages. Among them, in May 2026, the rabies vaccine (human diploid cells) for human use (freeze-dried) initiated Phase III clinical study in Chinese mainland.

(2) ***Cutting-edge Technology Platform Development: Strengthening Early-stage Innovation Capabilities and Building an Innovation Source***

The Group attaches great importance to the foundational role of its technology platforms, continues to strengthen its capabilities in identifying, nurturing and advancing early-stage innovative achievements, consolidates its core technology platforms including antibodies and ADC and new-generation small molecule drugs, and actively expands into frontier technologies such as radiopharmaceuticals, small nucleic acids, peptides and cell therapy. Furthermore, the Group utilizes AI digital intelligence tools to strengthen early-stage innovation capabilities and accelerate the transformation of R&D outcomes.

In the field of antibodies and ADC drugs, relying on the continuous enhancement of the antibody drug R&D capabilities of its subsidiary, Shanghai Henlius, the Group has established multiple biologics R&D platforms covering monoclonal antibodies, bispecific/multispecific antibodies and ADCs, and has formed a comprehensive technological system spanning from target discovery, antibody engineering, cell line development, to process development and large-scale manufacturing, which supports the global development and sustained output of biologic innovative drugs.

In the field of small-molecular innovative drugs, the Group focuses on the R&D of Best-in-Class (BIC) and First-in-Class (FIC) innovative drugs, integrates core functions for early drug discovery and clinical translation, and continuously enhances the R&D capabilities in small-molecular innovative drugs.

While consolidating the R&D capabilities of established technology platforms such as antibodies and ADC, small molecules, the Group also continues to focus on frontier technological directions with potential for breakthrough innovation. For example, in the field of cell therapy, during the Reporting Period, Fosun Kairos, a subsidiary, obtained approval from the NMPA for its IND application for FKC289 injection (an autologous dual-target CAR-T product targeting BCMA and CD19) for the treatment of relapsed/refractory primary light chain amyloidosis and relapsed/refractory membranous nephropathy; in the field of small nucleic acids, the IND application for FXR0906, a liver-targeted siRNA (small interfering RNA) drug for the treatment of hypertriglyceridemia, was approved by the NMPA in July 2026; in the field of radiopharmaceuticals, the investigator-initiated exploratory clinical trial (IIT) of SRT-017 ([225]Ac-PSMA-0057 injection), an alpha-nuclide radiotherapeutic drug, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) was initiated in Chinese mainland in July 2026, with the first subject dosed. As an alpha nuclide, 225Ac features high radiation energy and a short range, offering both tumor-killing potency and tissue precision. It currently represents one of the frontier technological directions in the field of radionuclide drug conjugates (RDCs).

(3) ***Deep Cultivation in Core Therapeutic Areas and Building Differentiated Competitive Advantages***

The Group has established its layout in "three major and three minor" therapeutic areas, with a focus on three core segments – oncology (solid tumors and hematologic tumors), immunology and inflammation, neurodegenerative diseases – while simultaneously expanding into therapeutic areas such as CVRM (cardiovascular, renal and metabolism), anti-infection as well as rare diseases, among others, and gradually establishing product pipelines and integrated solutions with long-term competitive strength.

Solid Tumors:

The Group continues to strengthen its layout in innovative pipelines centering on key indications such as breast cancer and lung cancer. During the Reporting Period, several antibodies and ADC drugs have entered key clinical trial stages and have approached the realization of commercial value:

- The serplulimab injection: 1 additional indication (neoadjuvant/adjuvant treatment of gastric cancer in combination with chemotherapy) was approved for launch in Chinese mainland; 3 additional indications (first-line treatment in combination with chemotherapy for squamous non-small cell lung cancer (sqNSCLC), esophageal squamous cell carcinoma (ESCC), and non-squamous non-small cell lung cancer (nsNSCLC)) were approved for launch in the EU.

- HLX43 (an anti-PD-L1 antibody-drug conjugate): multiple indications, including treatment of solid tumors such as advanced non-small cell lung cancer (NSCLC), recurrent/metastatic esophageal squamous cell carcinoma (ESCC), metastatic colorectal cancer (mCRC) and cervical cancer (CC), are in the Phase II clinical trial stage.

- HLX22 (recombinant humanized anti-HER2 monoclonal antibody): international multi-center Phase III clinical studies for solid tumors including gastric cancer are being conducted simultaneously in countries/regions including Chinese mainland, the U.S., the EU, Australia and Japan.

At the same time, the Group continues to refine its small-molecular innovative drug portfolio, for example:

- Fu Mai Ning (luvometinib tablets): during the Reporting Period, 1 additional indication (for pediatric and adolescent patients aged 2 years and older with relapsed or refractory Langerhans cell histiocytosis (LCH) after systemic treatment) was approved in Chinese mainland, filling the domestic treatment gap in this field; the registration application for another indication (for adult patients with neurofibromatosis type I (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection) was accepted and granted priority review.

- SAF-189 (foritinib succinate capsules): the NDA for non-small cell lung cancer has been accepted by the NMPA, and as at the date of this announcement, the on-site inspection for drug registration has been passed.

Hematological Tumors:

During the Reporting Period, the Group laid out the GR1803 pipeline through licensing, and its NDA for the treatment of multiple myeloma (MM) has been accepted by the NMPA; the self-developed Bcl-2 inhibitor FXS0683 for hematological malignancies was approved for clinical trials in Chinese mainland, and a Phase I clinical trial was initiated.

Immunology and Inflammation:

The Group continued to advance its innovative drug R&D in the field of immunology and inflammation. During the Reporting Period, IND applications for two indications of FKC289, the CAR-T cell therapy product (for relapsed/refractory primary light chain amyloidosis and relapsed/refractory membranous nephropathy), were approved by the NMPA; FXS6837 initiated Phase IIb clinical trials in Chinese mainland for the treatment of glomerular diseases associated with abnormal complement activation, such as IgA nephropathy. As at the date of this announcement, DPP1 inhibitor FXS7553 is in Phase II clinical trial stage in Chinese mainland for the treatment of both indications of non-cystic fibrosis bronchiectasis (NCFBE) and chronic obstructive pulmonary disease (COPD).

Neurodegenerative Diseases:

In response to the unmet clinical needs such as Alzheimer's disease and Parkinson's disease, the Group actively built an integrated ecosystem encompassing "diagnosis and therapy".

In terms of therapeutic drugs, during the Reporting Period, building upon the rights obtained to develop, register, manufacture and exclusively commercialize AR1001 in Chinese mainland, Hong Kong, Macau, and 10 agreed Southeast Asian countries, the Group further secured a global exclusive option for AR1001, with the right to exercise the option after the completion of the international multi-center Phase III clinical trial (POLARIS-AD study) for the treatment of early Alzheimer's disease and the provision of all Topline Data, thereby expanding the licensed territory to key global markets including the U.S., Europe and Japan, and would act as the marketing authorization holder in such regions. AR1001 is a small-molecule oral drug that acts as a highly selective phosphodiesterase-5 (PDE-5) inhibitor, intended for use in central nervous system (CNS) disease-related fields. Its international multi-center Phase III clinical trial for the treatment of early Alzheimer's disease completed LPLV (last patient, last visit) in July 2026; the post-marketing confirmatory clinical trial of sodium oligomannate capsule in Chinese mainland progressed steadily, with over 1,000 subjects accumulated and enrolled as of 31 July 2026, exceeding 50% of the clinical trial design protocol (planned enrollment of 1,950 subjects). In addition, HT001, an oral brain-penetrant NLRP3 inhibitor (for the treatment of Parkinson's disease) in-licensed by Hengtai Bio (an invested and incubated company), initiated Phase I clinical trials in Australia.

Alongside drug R&D, the clinical applications of the "MRgFUS" brain therapy system for indications such as medication-refractory idiopathic tremor and tremor-dominant Parkinson's disease have been continuously advanced. Meanwhile, the R&D of diagnostic reagents for neurodegenerative diseases has been actively advanced, and the capabilities in early screening and precise stratification have been improved, advancing the integration of diagnosis and therapy.

(4) ***Open-ended Innovation Ecosystem: Driving Sustainable Development with Multi-level Cooperation***

The Group consistently adheres to an open-ended R&D strategy, and builds a highly resilient innovation ecosystem through diversified collaboration models.

– Collaboration models: by integrating various models including independent R&D, collaborative development, licensing-in, fund incubation and industrial investment, the Group continuously enriches the innovative product pipelines and accelerates the translation and launch of innovative technologies and products.

– Early-stage layout: through industrial funds and other means, forward-looking investments are made in early-stage innovative projects. While establishing a flexible innovation pipeline mechanism, the Group effectively balances risks, thereby ensuring the continuity and forward-looking nature of its R&D system. During the Reporting Period, the Group enriched its pipeline layout in the field of liver disease treatment through an equity investment in Hepa Thera. Its main pipelines under development, HT-101 (a GalNAc-conjugated innovative siRNA drug), as well as the combination of HT-101 and HT-102 (a fully human monoclonal antibody), are in the Phase II clinical trial stage in Chinese mainland, and both have been included in the breakthrough therapy drug program by the NMPA.

(5) ***Progress in Global Two-Way License Cooperation***

The Group continues to advance global two-way license and co-development, and strengthen its capabilities for the integration of innovation resources and the translation of the global value. During the Reporting Period, Shanghai Henlius, a subsidiary, granted Eisai the rights to develop, manufacture and commercialize serplulimab injection in Japan in agreed field(s) and granted Abbott an exclusive commercialization license for serplulimab injection across an additional 42 agreed countries/regions in Asia, the Middle East, Africa and Eastern Europe, in agreed field(s). Fosun Pharma (Shenzhen), a subsidiary, was granted exclusive rights for the research, development, registration, manufacture and commercialization of FXR0906, a liver-targeted siRNA (small interfering RNA) drug, in Chinese mainland, Hong Kong and Macau; Yao Pharma, a subsidiary, was granted exclusive rights for the clinical development and commercialization of GR1803 in Chinese mainland, Hong Kong, Macau, and Taiwan region, in agreed field(s), and will serve as the marketing authorization holder (MAH) for the product in the licensed territory; and Fosun Wanbang, a subsidiary, was granted rights for the development, registration, manufacture and commercialization of rosoquelimab (anti-IL-17A mAb, project code: JS005) in Chinese mainland, Hong Kong, Macau and Taiwan region, in agreed field(s), continuously enriching its high-value pipeline portfolio in the field of immunology and inflammation.

2. ***Deepening Globalization: Building a Globally Integrated Operating System Across the Entire Value Chain***

The Group has continuously deepened its globalization across multiple dimensions, including innovative R&D, manufacturing quality, registration, commercialization and academic influence. It has established a global operational network covering markets such as China, the United States, Europe, Africa, India, the Middle East and Southeast Asia. Its globalization model has been continuously upgraded from "product exporting" to "system exporting". Moving forward, the Group will remain patient-centered, deepen its market presence in key regions, and foster global partnerships, so as to drive the stable development of its globalized business.

(1) ***R&D: Deepening Global Clinical Synergies to Accelerate Product Value Transformation***

The Group adheres to a core strategy driven by innovative R&D, integrates global clinical resources to systematically advance the clinical translation and market access of key products in major markets, and builds the global quality standards and regulatory compliance system. During the Reporting Period, the Group continued to conduct multiple international multi-centre clinical studies and as at the end of the Reporting Period, several products (such as serplulimab injection, HLX43 and HLX22) had been granted Orphan-drug Designation in the U.S., the EU, and other markets.

(2) ***Manufacturing and Quality: Global Footprint Strengthening the Supply Foundation***

The Group continuously drives the alignment of its manufacturing system with international quality standards and deepens its global production capacity layout. In particular, the biologics production lines of Shanghai Henlius, a subsidiary, have normalized supply to markets including China, Europe, Canada, Latin America, Southeast Asia and India, while Gland Pharma's injection production lines have covered markets including the U.S., Europe, and others. The internationalization of production standards ensures the stability and quality control of the global supply chain.

(3) ***Registration: Enhancing Global Regulatory Affairs Systems and Submission Capabilities***

The Group consistently adheres to a clinical value-oriented approach, and has constructed a registration network covering core global markets including China, the U.S., Europe, Japan, India, Africa, Southeast Asia, and the Middle East, building the capability in global registration based on integrated R&D and manufacturing characterized by "breakthrough in Europe and the U.S., and deep cultivation in emerging markets." This forward-looking initiative propels the Group into an intensive realization period for obtaining global approvals for launch of its Innovative Drugs.

(4) ***Commercialization: Multi-Model Deployment to Build Mature International Operational Capabilities***

The Group continues to build a professional, digital and compliant commercialization system, and has established dedicated sales teams focusing on oncology (hematology, breast cancer, lung cancer), immunology and inflammation and CVRM (cardiovascular, gastrointestinal, nephrology). As at the end of the Reporting Period, the Group's commercialization teams cover major markets including China, the U.S. and Africa with more than 6,000 employees, and regional distribution centers were established in emerging markets such as Africa and Southeast Asia.

The Group adopts a dual-track model of licensing and self-operation to conduct commercialization in the overseas markets. In the U.S. market, the Group has actively promoted the sales of generic drugs and the preparation for the launch of new products such as innovative drugs and respiratory and medical cosmetology devices, continuously strengthening its commercialization capabilities in the U.S. market. As at the date of this announcement, serplulimab injection has been approved for launch in around 50 countries and regions and included in the national medical insurance drug catalogues of 12 EU countries. In the Japanese market, during the Reporting Period, the rights to develop, manufacture and commercialize serplulimab injection in Japan in agreed field(s) were granted to Eisai, thereby accelerating its commercialization process. In emerging markets across Southeast Asia, the Middle East, South America, and Africa, leveraging its advantages in innovative R&D and high-standard manufacturing, the Group has continuously provided high-quality innovative drugs, complex formulations, and generic drugs that combine clinical value with affordability, helping to enhance local healthcare accessibility. Among these, in the African market, a marketing network covering over 40 countries and regions has been established; in the Southeast Asian and Middle Eastern markets, the roll-out of innovative products will be accelerated through strategic partnerships; in the Middle East market, a joint venture was established in Saudi Arabia with SVAX, a Saudi Arabian pharmaceutical enterprise, to promote the entry of innovative and high-value drugs/products in therapeutic areas such as oncology and autoimmune diseases into the MENAT region (Middle East, North Africa, and Turkey). During the Reporting Period, a licensing agreement was also entered into with Abbott, granting it an exclusive commercialization license for serplulimab injection across 42 agreed countries/regions in Asia, the Middle East, Africa, and Eastern Europe, thereby further deepening its footprint in emerging markets.

In terms of the medical devices business, Sisram Medical, a subsidiary, has continued to expand its global market by strengthening a strategy combining digital channels with direct sales and distribution. As at the end of the Reporting Period, it had established 12 direct-sales offices worldwide, with a marketing network spanning over 110 countries and regions. Breas, a subsidiary, has set up 9 subsidiaries globally, with a marketing network covering around 60 countries and regions.

(5) ***Academic Influence: Delivering High-quality Clinical Data and Strengthening International Professional Recognition***

As at the date of this announcement, clinical data for multiple pipeline, incubated and marketed products have been presented at global academic conferences including the American Society of Clinical Oncology (ASCO), the Chinese Society of Clinical Oncology (CSCO), the Annual Meeting of the American Association for Cancer Research (AACR), the European Society for Medical Oncology (ESMO), the European Hematology Association (EHA), Neurofibromatosis Conference (NF Conference), Association for Research in Otolaryngology (ARO) and International Society for the Study of Vascular Anomalies (ISSVA), as well as published in leading global journals including The Lancet, Nature Medicine and Drugs. During the Reporting Period, clinical research of three of the Group's innovative drug pipelines in development were selected for oral presentations at the 2026 ASCO Annual Meeting, including the Phase III study of Luvometinib (Fu Mai Ning) in adults with NF1, the Phase III study of serplulimab injection (Han Si Zhuang) in perioperative gastric cancer (ASTRUM-006), and clinical research of HLX43 in non-small cell lung cancer. In addition, 10 studies were selected for poster presentations at the 2026 ASCO, including data from two Phase III studies of fovinaciclib citrate capsules (Fu Tuo Ning) and a study on HLX43 in nasopharyngeal carcinoma. Through the continuous delivery of high-quality clinical outcomes, the Group's professional influence in the global medical community has steadily increased, providing solid academic support for the international registration and global commercial expansion of its products.

3. ***Fully Embracing AI: Continuous Growth in Digitalization and AI-empowered Business***

The Group continues to deepen its digitalization and AI strategic layout, and systematically advances the platformization, engineering and scaled implementation of AI capabilities focusing on core aspects such as new drug R&D, clinical research, products and services, and operation management. On this basis, the fully AI-embracing strategy centered on FoSTRAID (Fosun Pharma Strategic Transformation via AI & Data science) was further defined and steadily advanced. By integrating resources, a digital – intelligence architecture that promotes synergistic development across "foundation – platform – data – agent – scenario – mechanism" has been established, systematically driving the deep integration of AI into key aspects including early drug R&D, clinical development, production and operation, and post-launch lifecycle management.

During the Reporting Period, the Group completed the upgrade of the "PharmAID® Pharmaceutical Intelligence System V2.0," forming four major segments: taking the "PharmaSight Decision Management Platform" as the top-level decision-maker, relying on the "AquaVista Data Integration Platform" to continuously consolidate the data foundation, and prioritizing the development of the "Astrolabe Early Research Intelligence Platform" and "MedAlkaid Clinical Research Intelligence Platform" to promote AI empowerment across the entire lifecycle of the product pipeline from early R&D to clinical confirmation and post-marketing; aiming to comprehensively support core functions including strategic decision-making, operation management, early research, clinical research, and data knowledge foundation. Meanwhile, general empowerment tools including agent crowdsourcing systems, intelligent skill bases, knowledge bases, model bases, AI arenas and operational digital dashboards were launched concurrently to enhance the full-stack AI support system.

During the Reporting Period, AI was progressively and deeply embedded into core business processes, providing support across various business lines including R&D, production, marketing and healthcare services. As at the end of the Reporting Period, more than 25 high-value AI projects had been brought into production and over 50 scenarios were being advanced concurrently, covering business lines such as pharmaceutical project evaluation, target prediction, molecular optimization, clinical trials, pharmacovigilance, medical writing, multi-engine and multi-step in-depth research reports, patent insights, smart manufacturing, cold chain, hospital diagnosis and treatment management, and intelligent office operations; over 500 AI requirements were accumulated, and nearly 400 self-developed AI agents were created by employees. Among these, AI tools for medical translation and professional in-depth research reports recorded over 100,000 cumulative calls, while AI medical Q&A and DocuSight/in-depth research report tools recorded over 40,000 calls; AI digital tools were deployed in the early-stage molecular pipeline development of certain new drugs, and as at the end of the Reporting Period, 2 new molecules generated and structured with AI-assisted had entered the PCC stage.

During the Reporting Period, the Company received special support for "AI + Manufacturing" from the Shanghai Municipal Commission of Economy and Informatization, partnered with Zhongshan Hospital Affiliated to Fudan University*(復旦大學附屬中山醫院) to jointly build a professional research protocol review AI agent, established an AI co-creation center in the Greater Bay Area, served as a judge in the life sciences category of the World Artificial Intelligence Conference AI Competition, participated in the Bio-IT World Conference & Expo as well as other authoritative industry conferences including DIA (Drug Information Association) and CMAC (Beijing Collaboration Medical Advance Center), where it delivered special reports and poster displays, and engaged in joint research topics with scientific research institutes, continuously facilitating the co-construction of a government-industry-academia-research-medical ecosystem.

II. Segment Performance Overview

1. Pharmaceutical manufacturing

Performance summary

During the Reporting Period, with regard to the pharmaceutical manufacturing business, the Group intensified its support and development efforts for innovative products, and focused on its core therapeutic areas. The Group continued to advance business streamlining and consistently strengthened the integrated operation of its three major systems of R&D, manufacturing and marketing to enhance efficiency, while continuously promoting cost reduction and efficiency improvement. In the first half of 2026, the pharmaceutical manufacturing business of the Group recorded revenue of RMB14,727 million, representing a period-on-period increase of 6.59%. Among which, revenue from Innovative Drugs amounted to RMB4,911 million, representing a period-on-period increase of 13.84%, and products such as Han Bei Tai, Han Nai Jia and Akynzeo demonstrated strong market performance, effectively driving the growth of revenue from Innovative Drugs. In the first half of 2026, segment results amounted to RMB1,834 million, representing a period-on-period increase of 13.42%, while segment profit amounted to RMB1,698 million, representing a period-on-period increase of 6.99%.

During the Reporting Period, the Group continuously consolidated its innovative R&D platform, concentrated on advantageous pipelines, and enhanced efficiency by integrating R&D resources. At the same time, through diversified and multi-tiered innovative R&D models such as independent R&D, co-development, licensed-in projects, fund incubation and industrial investment, the Group continuously enriched its innovative product matrix and steadily implemented its innovative transformation. During the Reporting Period, the total R&D expenditure in the pharmaceutical manufacturing business amounted to RMB3,046 million, representing a period-on-period increase of 32.72%; of which R&D expenses reached RMB1,898 million, representing a period-on-period increase of 29.20%. R&D expenditure related to Innovative Drugs reached RMB2,650 million, representing a significant period-on-period increase of 48.38%; R&D expenditure in Innovative Drugs accounted for 81.61% of the Group's total R&D expenditure, representing a period-on-period increase of 12.50 percentage points, and accounted for 87.00% of the pharmaceutical manufacturing business's R&D expenditure, representing a period-on-period increase of 9.18 percentage points. It mainly covered investments in pipelines such as HLX43, HLX22, GR1803 and FXR0906, as well as technology platforms including new-generation small molecule drugs and radiopharmaceuticals, with resources continuously tilting towards innovative drugs.

Revenue from major products in the major therapeutic areas under the pharmaceutical manufacturing business of the Group during the Reporting Period is set out in the following table:

Unit: million Currency: RMB

Major therapeutic area	**Jan-Jun 2026**	Jan-Jun 2025*	Period-on-period change on the same basis
Major products of tumor and immune modulation *(Note)*	**4,632**	4,314	7.37%
Major products of anti-infection *(Note)*	**1,870**	1,656	12.92%
Major products of metabolism and alimentary system *(Note)*	**1,405**	1,306	7.58%
Major products of cardiovascular system *(Note)*	**960**	926	3.67%
Major products of central nervous system *(Note)*	**480**	492	-2.44%
Major products of APIs and intermediate products *(Note)*	**549**	607	-9.56%

Note: Major products of tumor and immune modulation comprise: Trastuzumab for injection (Brand name in Chinese mainland: Han Qu You) and trastuzumab drug substance, Han Li Kang (rituximab injection), Serplulimab injection (Brand name in Chinese mainland: Han Si Zhuang), Akynzeo (netupitant and palonosetron hydrochloride capsules), Yi Kai Da (ejilunsai injection), Han Bei Tai (bevacizumab injection), Han Nai Jia (neratinib maleate tablets), Pei Jin (telpegfilgrastim injection), Su Ke Xin (avatrombopag maleate tablets), Han Da Yuan (adalimumab injection), Kai Lai Zhi (epinastine hydrochloride capsules), Ke Sheng (Xihuang capsules), Zhao Hui Xian (bicalutamide tablets), Fu Ke Shu (anti-human T-lymphocyte rabbit immunoglobulin), Fu Mai Ning (luvometinib tablets), Otezla (apremilast tablets), Denosumab injection, paclitaxel, Yi Luo Ze/Tu Mei Si (pemetrexed disodium for injection), ondansetron, Fu Tuo Ning (fovinaciclib citrate capsules), Di Kai Mei (sorafenib tosylate tablets), Han Bei You (pertuzumab injection), and oxaliplatin.

Major products of anti-infection comprise: antimalarial series such as artesunate, rabies vaccine (Vero cell) for human use (freeze-dried), Cravit (levofloxacin tablets), daptomycin, Cravit (levofloxacin injection), Pai Shu Xi Lin (piperacillin sodium and tazobactam sodium for injection), micafungin, anti-tuberculosis series, caspofungin, vancomycin, He Pu Ding (lamivudine tablets), Xi Chang/Bi Li Shu (cefmetazole sodium for injection), Qiang Shu Xi Lin/Qin Shu/Er Ye Qin (piperacillin sodium and sulbactam sodium for injection), Sha Duo Li Ka (potassium sodium dehydroandrographolide succinate for injection), Comirnaty (mRNA COVID-19 vaccine), Er Ye Bi (ceftizoxime sodium for injection), Si Ke Ni (azithromycin capsules), Sai Fu Nuo (cefminox sodium for injection), and rabies vaccine (VERO cell) for human use (non-freeze-dried).

Major products of metabolism and alimentary system comprise: You Li Tong (febuxostat tablets), Atomolan (glutathione tablets), Bei Wen (keverprazan hydrochloride tablets), Ke Yi (new compound aloe capsules), animal insulin and its preparations, Atomolan (glutathione for injection), Pu Rui Ni (pretomanid tablets), Yi Bao (recombinant human erythropoietin for injection (CHO cells)), Li Qing (alfacalcidol tablets), Wan Su Jing (empagliflozin tablets), human insulin and its preparations, Wan Su Ping (glimepiride tablets), Wan Ti Le (tenapanor hydrochloride tablets), Pang Bi Fu (etelcalcetide hydrochloride injection), and Bei Yi (potassium chloride granules).

Major products of cardiovascular system comprise: heparin series preparations, Yi Xin Tan (sacubitril valsartan sodium tablets), Bang Tan (telmisartan tablets), Ya Ni An (amlodipine besylate tablets), Ke Yuan (calcium dobesilate capsules), Bang Zhi (pitavastatin calcium tablets), Xin Xian An (meglumine adenosine cyclophosphate injection), You Di Er (alprostadil dried emulsion for injection), Su Ka Xin (indapamide tablets), and propranolol hydrochloride injection.

Major products of central nervous system comprise: Qi Wei (quetiapine fumarate tablets), lorazepam tablets, rocuronium bromide, Ao De Jin (deproteinized calf blood serum injection), Chang Tuo Ning (penehyclidine hydrochloride injection), Qi Cheng (escitalopram oxalate tablets), and dexmedetomidine.

Major products of APIs and intermediates products comprise: amino acid series, tranexamic acid, levamisole hydrochloride, and clindamycin hydrochloride.

* The data for January to June 2025 was restated according to the basis for January to June 2026.

R&D innovation

The Group has progressively established a high-value pipeline portfolio focusing on three core therapeutic areas including oncology (solid tumors, hematologic tumors), immunology and inflammation, neurodegenerative diseases. Moving forward, the Group will continue to consolidate its core technology platform capabilities, which encompass antibodies and ADC and new-generation small molecule drugs, while actively expanding its presence in cutting-edge technologies such as radiopharmaceuticals, small nucleic acids, peptides and cell therapy. Furthermore, the Group will utilize AI digital intelligence tools to strengthen early-stage innovation capabilities and accelerate the transformation of R&D outcomes.

To promote the implementation of the innovation strategy in a high-quality manner and to continuously enhance R&D efficiency, a Scientific Advisory Board ("SAB") at the group level, mainly composed of the "external think tank", has been established to provide strategic guidance and insights assisting the management of the Group in formulating and optimizing the medium- and long-term innovation strategy. The Group has also formed a pipeline committee composed of internal experts to formulate science-driven overall R&D strategies and plans and manage product portfolios. The Group continues to recruit seasoned scientists and high-level talent to comprehensively upgrade capabilities across early-stage R&D, CMC, clinical medicine and clinical operations.

During the Reporting Period, 7 Innovative Drugs with a total of 20 indications, and over 30 generic drug varieties were approved for launch both domestically and internationally; 4 Innovative Drugs and over 30 generic drug varieties were applied for launch both domestically and internationally; in addition, around 30 clinical trial applications of Innovative Drugs were approved by domestic and overseas regulatory institutions. During the Reporting Period, a total of 185 patents had been applied for in the pharmaceutical manufacturing segment of the Group, including 5 U.S. patent applications and 14 PCT applications; 26 invention patent authorizations were granted.

For details on the updates on the Group's major R&D pipelines during the Reporting Period, please refer to Table 1.

Table 1: Major Pipeline Progress Achieved during the Reporting Period

Progress during the Reporting Period	Drug name/code	Target	Drug category	Indications	IND approved	Phase I	Phase II	Phase III	NDA accepted	Approved for launch	Remarks
Approved for launch	Luvometinib Tablets (Brand Name in Chinese mainland: Fu Mai Ning)	MEK1/2	Chemical drug	New indication: Langerhans cell histiocytosis (LCH) in children and adolescents							–
	Fortacin Spray (Lidocaine and Prilocaine Aerosol)	–	Chemical drug	Primary premature ejaculation in adult men							–
	Serplulimab Injection (Brand Name in Chinese mainland: Han Si Zhuang; Brand Name in the EU: Hetronifly®)	PD-1	Therapeutic biological product	New indication: combination chemotherapy for neoadjuvant/adjuvant treatment of gastric cancer (GC)							–
			Biological product	Approved indications in the EU: (1) combination chemotherapy as first-line treatment for esophageal squamous cell carcinoma (ESCC); (2) combination chemotherapy as first-line treatment for non-squamous non-small cell lung cancer (nsNSCLC); (3) combination chemotherapy as first-line treatment for squamous non-small cell lung cancer (sqNSCLC)							The progress is in the areas that have been licensed-out
	HLX11 (Pertuzumab Injection) (Brand Name in Chinese mainland: Han Bei You; Brand Name in the EU: POHERDY®)	HER2	Therapeutic biological product	(1) Neoadjuvant/adjuvant therapy for HER2-positive early breast cancer; (2) metastatic breast cancer							–
			Biological product	Approved indications in the EU: (1) neoadjuvant/adjuvant therapy for HER2-positive early breast cancer; (2) all indications of the reference drug approved in the EU, including metastatic breast cancer							The progress is in the areas that have been licensed-out

Progress during the Reporting Period	Drug name/code	Target	Drug category	Indications	IND approved	Phase I	Phase II	Phase III	NDA accepted	Approved for launch	Remarks
Approved for launch	HLX14 (Denosumab Injection) (Brand Name in Canada: BILODYOS®, specification: 60mg/mL)	RANKL	Biological product	Approved indications in Canada: 5 indications approved locally for the reference drug, including osteoporosis							The progress is in the areas that have been licensed-out
	HLX14 (Denosumab Injection) (Brand Name in Canada: TUZEMTY®, specification: 120mg/1.7mL)			Approved indications in Canada: 3 indications approved locally for the reference drug, including skeletal-related events							The progress is in the areas that have been licensed-out
	Rituximab Injection (Brand Name in Chinese mainland: Han Li Kang)	CD20	Therapeutic biological product	New indications: (1) combination chemotherapy for the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL); (2) combination chemotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not eligible for hematopoietic stem cell transplantation							–
NDA accepted	Luvometinib Tablets (Brand Name in Chinese mainland: Fu Mai Ning)	MEK1/2	Chemical drug	Neurofibromatosis type I (NF1) (adults)							–
	SAF-189 (Foritinib Succinate Capsules)	ALK	Chemical drug	Non-small cell lung cancer (ALK+)							–
	ET-26 (Etomidate Hydrochloride Injection)	–	Chemical drug	Induction of anesthesia and anesthesia for short surgical procedures							–
	HLX04 (Bevacizumab Injection)	VEGF	Biological product	Indications applied in the U.S.: (1) Metastatic colorectal cancer; (2) non-squamous non-small cell lung cancer; (3) glioblastoma; (4) renal cell carcinoma; (5) ovarian cancer; (6) carcinoma of the cervix							–

Progress during the Reporting Period	Drug name/code	Target	Drug category	Indications	IND approved	Phase I	Phase II	Phase III	NDA accepted	Approved for launch	Remarks
Under Phase III clinical study	Rabies vaccine (human diploid cells) for human use (freeze-dried)	–	Preventive biological product	Rabies prophylaxis							–
Under Phase II clinical study	Luvometinib Tablets* (Brand Name in Chinese mainland: Fu Mai Ning)	MEK1/2	Chemical drug	In combination with anlotinib for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS)-mutated advanced non-small cell lung cancer (NSCLC)							–
	FXS4640	PLK1	Chemical drug	In combination with FOLFOX or FOLFIRI and bevacizumab for RAS-mutated metastatic colorectal cancer							–
	FXS5626	TYK2/JAK1	Chemical drug	Non-infectious uveitis							–
	HLX22 (Recombinant humanized anti-HER2 monoclonal antibody Injection) + HLX87 (Antibody-drug conjugate targeting HER2)	HER2+HER2 ADC	Therapeutic biological product	HER2-positive recurrent or metastatic breast cancer (BC)							*Note 1*
	HLX43 (PD-L1-targeted ADC) monotherapy or in combination with HLX07 (Recombinant anti-EGFR humanised monoclonal antibody injection)	PD-L1/PD-L1+ EGFR	Therapeutic biological product	Advanced/metastatic squamous non-small cell lung cancer (NSCLC)							*Note 2,* also approved for a clinical trial in Japan
	HLX43 (PD-L1-targeted ADC)	PD-L1	Biological product	Advanced non-small cell lung cancer (NSCLC) (EU)							–
	HLX07 (Recombinant anti-EGFR humanised monoclonal antibody injection) *+ serplulimab injection + chemotherapy	EGFR+PD-1	Therapeutic biological product	Advanced squamous non-small cell lung cancer (sqNSCLC)							*Note 3,* also approved for a clinical trial in Australia

Progress during the Reporting Period	Drug name/code	Target	Drug category	Indications	IND approved	Phase I	Phase II	Phase III	NDA accepted	Approved for launch	Remarks
Under Phase I clinical study	FXS0887	ATR	Chemical drug	Advanced malignant solid tumors							–
	FXB0871*	PD-1/IL-2	Therapeutic biological product	Locally advanced or metastatic solid tumors							–
	FXS0683*	Bcl-2	Chemical drug	Hematologic malignancies							–
	HLX43 (PD-L1-targeted ADC) + HLX07 (Recombinant anti-EGFR humanised monoclonal antibody injection) or serplulimab injection	PD-LI+EGFR/ PD-LI+PD-1	Therapeutic biological product	Advanced or metastatic colorectal cancer							*Note 4*
	HLX701 (Recombinant human SIRPα-IgG4 Fc fusion protein injection) *+ cetuximab + chemotherapy	CD47	Therapeutic biological product	Advanced colorectal cancer (CRC)							*Note 5*
	HLX316 (B7-H3-targeting sialidase Fc fusion protein)*	B7-H3	Therapeutic biological product	Advanced/metastatic solid tumors							–
	HLX3901 (DLL3x DLL3xCD3x CD28 tetra-specific antibodies)*	DLL3x DLL3x CD3x CD28	Therapeutic biological product	Advanced small cell lung cancer or neuroendocrine carcinoma							–
	HLX48 (Antibody-drug conjugate targeting c-MET and EGFR) *	c-METx EGFR	Therapeutic biological product	Advanced/metastatic solid tumors							Also approved for a clinical trial in Australia
	HLX97 (KAT6A/B Small Molecule Inhibitor) *	KAT6A/B	Chemical drug	Advanced/metastatic solid tumors							–
	HLX13 (Recombinant anti-CTLA-4 fully human monoclonal antibody injection)	CTLA-4	Biological product	Hepatocellular carcinoma (HCC) (U.S.)							The progress is in the areas that have been licensed-out

Progress during the Reporting Period	Drug name/code	Target	Drug category	Indications	IND approved	Phase I	Phase II	Phase III	NDA accepted	Approved for launch	Remarks
Under Phase I clinical study	HLX15-SC (Recombinant anti-CD38 fully human monoclonal antibody injection-subcutaneous injection)*	CD38	Therapeutic biological product	Multiple myeloma (MM)							Also approved for a clinical trial in U.S. (where the region has been licensed-out)
	HLX17 (Recombinant humanised anti-PD-1 monoclonal antibody injection)	PD-1	Biological product	Multiple resected solid tumours (U.S.)							–
	HLX319 (Pertuzumab and trastuzumab injection (subcutaneous injection)) *	HER2+ HER2	Therapeutic biological product	Adjuvant/neoadjuvant treatment of HER2-positive early or locally advanced breast cancer, and metastatic breast cancer							–
IND approved	FKC289	BCMA+ CD19	Therapeutic biological product	Relapsed/refractory primary light-chain amyloidosis							–
				Relapsed/refractory membranous nephropathy							–
	LBP-ShC4	–	Chemical drug	Androgenetic alopecia (AGA)							–
	HLX43 (PD-L1-targeted ADC) + HLX07 (Recombinant anti-EGFR humanised monoclonal antibody injection)+ serplulimab injection	PD-L1+ EGFR+PD-1	Therapeutic biological product	Advanced solid tumors							–
	HLX43 (PD-L1-targeted ADC)+ serplulimab injection	PD-L1+PD-1	Biological product	Neoadjuvant non-small cell lung cancer (NSCLC) (Australia)							–
	HLX3902 (STEAP1xCD3x CD28 trispecific antibody)	STEAP1x CD3xCD28	Therapeutic biological product	Metastatic castration-resistant prostate cancer and other advanced solid tumors (Chinese mainland, Australia)							*Note 6*
	HLX18 (Recombinant anti-PD-1 humanized monoclonal antibody injection)	PD-1	Therapeutic biological product	Solid tumors							*Note 7*
	HLX05-N (Recombinant anti-EGFR chimeric human-murine monoclonal antibody injection)	EGFR	Therapeutic biological product	Metastatic colorectal cancer (Chinese mainland, U.S.)							*Note 8*
	HLXTE-HAase02 (recombinant human hyaluronidase injection)	–	Therapeutic biological product	Facilitate the diffusion and absorption of drugs administered via subcutaneous injection or subcutaneous infusion							–

* *Investigational drugs that were approved for clinical trials and entered the corresponding clinical study stages during the Reporting Period.*

Note: Unless otherwise specified, the pipeline progress set out above relates to developments within Chinese mainland.

Note 1: In February 2026, a Phase II/III clinical trial of HLX22 in combination with HLX87 as a first-line treatment for HER2-positive recurrent or metastatic breast cancer was initiated in Chinese mainland.

Note 2: In May 2026, an international multi-center Phase II/III clinical trial of HLX43 as monotherapy or in combination with HLX07 for the treatment of advanced/metastatic squamous non-small cell lung cancer (NSCLC) was initiated in Chinese mainland.

Note 3: In May 2026, an international multi-center Phase II/III clinical trial of HLX07 in combination with serplulimab injection and chemotherapy for the treatment of advanced squamous non-small cell lung cancer (sqNSCLC) was initiated in Chinese mainland.

Note 4: In February 2026, a Phase Ib/II clinical trial of HLX43 in combination with HLX07 or serplulimab injection for the treatment of advanced or metastatic colorectal cancer was initiated in Chinese mainland.

Note 5: In March 2026, a Phase Ib/II clinical trial of HLX701 in combination with cetuximab and chemotherapy for the treatment of advanced colorectal cancer was initiated in Chinese mainland.

Note 6: In July 2026, a Phase I clinical trial of HLX3902 for the treatment of metastatic castration-resistant prostate cancer and other advanced solid tumors was initiated in Chinese mainland.

Note 7: In July 2026, an international multi-center Phase I clinical trial of HLX18 for the treatment of solid tumors was initiated in Chinese mainland.

Note 8: In July 2026, a Phase I clinical trial of HLX05-N for the treatment of metastatic colorectal cancer was initiated in Chinese mainland.

As at the end of the Reporting Period, there were more than 80 major pipeline projects of the Group on Innovative Drugs (calculated by indications); please refer to Table 2 to Table 4 for details.

Table 2: Major Pipelines for Innovative Drugs

Therapeutic area	Technology platform	Drug name/code	Target	Indications	IND approved	Phase I	Phase II	Phase III	NDA accepted	Approved for launch	Remarks *Note*
Solid tumors	Antibody	Serplulimab injection + chemotherapy	PD-1	Neoadjuvant/adjuvant treatment of gastric cancer							–
				Extensive-stage small cell lung cancer (ES-SCLC)							Bridging trial (U.S., Japan), with Japan having been licensed-out
		HLX903	EGFR	Non-small cell lung cancer							*Note 1*
		Serplulimab injection + chemotherapy + radiotherapy	PD-1	Limited-stage small cell lung cancer (LS-SCLC)							International multi-center
		Serplulimab injection + bevacizumab + chemotherapy	PD-1+VEGF	Metastatic colorectal cancer (mCRC)							International multi-center
		HLX22 + standardized treatment[1]	HER2 + HER2	HER2-positive locally advanced or metastatic gastroesophageal junction and gastric cancer (GC)							International multi-center
		Serplulimab injection + HLX07	PD-1+EGFR	Squamous non-small cell lung cancer (sqNSCLC), etc.							–
		HLX22 + standardized treatment/detrastuzumab	HER2 + HER2 ADC	HER2-low expressing, HR-positive locally advanced or metastatic breast cancer							–
		HLX07	EGFR	Solid tumor							Also approved for a clinical trial in U.S.
				Locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)							Also approved for a clinical trial in U.S.
		HLX22+HLX87	HER2 + HER2 ADC	HER2-positive recurrent or metastatic breast cancer (BC)							–

[1] Trastuzumab in combination with chemotherapy; the same applies below.

Therapeutic area	Technology platform	Drug name/code	Target	Indications	IND approved	Phase I	Phase II	Phase III	NDA accepted	Approved for launch	Remarks [Note]
Solid tumors	Antibody	HLX07 + serplulimab injection + chemotherapy	EGFR+PD-1	Advanced squamous non-small cell lung cancer (sqNSCLC)							International multi-center
		HLX3901	DLL3xDLL3x CD3xCD28	Advanced small cell lung cancer or neuroendocrine carcinoma							–
		HLX37	PD-L1x VEGF	Advanced/metastatic solid tumors							–
		HLX22 + serplulimab injection + standardized treatment	HER2 + PD-1	HER2-positive advanced gastric cancer							–
		HLX22+HLX87	HER2 + HER2 ADC	Neoadjuvant treatment of HER2-positive breast cancer (BCneo)							–
		HLX3902	STEAP1x CD3x CD28	Metastatic castration-resistant prostate cancer (mCRPC) and other advanced solid tumors (Chinese mainland, Australia)							*Note 2*
	ADC	FS-1502	HER2	HER2-positive locally advanced or metastatic breast cancer							–
		HLX43	PD-L1	Advanced non-small cell lung cancer (NSCLC)							International multi-center
				Recurrent/metastatic ESCC, mCRC, CC, etc.							–
		HLX43 + serplulimab injection	PD-L1+PD-1	Advanced/metastatic solid tumors							–
		HLX43 as monotherapy or in combination with HLX07	PD-L1/ PD-L1+EGFR	Advanced/metastatic squamous non-small cell lung cancer (NSCLC)							International multi-center
		HLX43	PD-L1	Advanced/metastatic solid tumors							In particular, the trial for thymic cancer (TC) is an international multi-center trial
		HLX43+HLX07	PD-L1+EGFR	Advanced/metastatic solid tumors							–
		HLX43 + HLX07 or serplulimab injection	PD-L1+EGFR/ PD-L1+PD-1	Advanced or metastatic colorectal cancer							–
		HLX48	EGFR+c-MET	Advanced/metastatic solid tumors							Also approved for a clinical trial in Australia
		HLX43 + serplulimab injection	PD-L1+PD-1	Neoadjuvant non-small cell lung cancer (NSCLC) (Australia)							–
		HLX43+HLX07+ serplulimab injection	PD-L1+EGFR +PD-1	Advanced solid tumors							–

Therapeutic area	Technology platform	Drug name/code	Target	Indications	IND approved	Phase I	Phase II	Phase III	NDA accepted	Approved for launch	Remarks [Note]
Solid tumors	Small molecule	Fu Mai Ning (luvometinib tablets, project code: FCN-159)	MEK1/2	Langerhans cell histiocytosis (LCH) in children and adolescents	■	■	■	■	■	■	–
		SAF-189 (foritinib succinate capsules)	ALK	Non-small cell lung cancer (ALK+)	■	■	■	■	■		Also approved for a clinical trial in U.S.
		Fu Mai Ning (luvometinib tablets, project code: FCN-159)	MEK1/2	Neurofibromatosis type I (NF1) (adults)	■	■	■	■	■		–
				Low-grade glioma (children)	■	■	■	■			–
		HLX78 (lasofoxifene tablets)	Selective estrogen receptor modulator	Breast cancer	■	■	■	■			International multi-center
		FXS4640 (original project code: XS-03)	PLK1	In combination with FOLFOX or FOLFIRI and bevacizumab for RAS-mutated metastatic colorectal cancer	■	■	■				–
		Fu Mai Ning (luvometinib tablets, project code: FCN-159)	MEK1/2	In combination with anlotinib for advanced non-small cell lung cancer (NSCLC) harboring Kirsten rat sarcoma viral oncogene (KRAS) mutations	■	■	■				–
		FXS7490 (original project code: XS-02)	CHK1	Advanced solid tumors	■	■					–
		FXS0887	ATR	Advanced malignant solid tumors	■	■					–
		HLX97	KAT6A/B	Advanced/metastatic solid tumors	■	■					–
	Radioph-armaceuticals	SRT-007	PSMA	PSMA-positive mCRPC	■	■					*Note 3*
	Others	HLX701 + cetuximab + chemotherapy	CD47	Advanced colorectal cancer (CRC)	■	■					–
		HLX316	B7-H3	Advanced/metastatic solid tumors	■	■					–
		FXB0871	PD-1/IL-2	Locally advanced or metastatic solid tumors	■	■					–
		VT-101	–	Advanced head and neck squamous cell carcinoma, melanoma, breast cancer and other solid tumors (Chinese mainland, U.S.)	■						–

Therapeutic area	Technology platform	Drug name/code	Target	Indications	IND approved	Phase I	Phase II	Phase III	NDA accepted	Approved for launch	Remarks [Note]
Hematological tumors	Antibody	GR1803	BCMA/CD3	Multiple myeloma (MM)							*Note 4*
	Cell therapy	FKC889 (brexucabtagene autoleucel injection)	CD19	Adult r/r ALL							–
				Adult r/r MCL							–
		Yi Kai Da (ejilunsai injection)	CD19	Relapsed or refractory indolent non-Hodgkin lymphoma (r/r iNHL)							–
		FKC516	CD20	Relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL)							–
	Small molecule	FXS5960 (original project code: XS-04)	IRAK4/BTK/ FLT3	Hematological tumors							–
		FXS0683	Bcl-2	Hematological tumors							–
Immunology and inflammation	Antibody	JS005	IL-17A	Moderate-to-severe plaque psoriasis							*Note 5*
				Active ankylosing spondylitis							
		HLX6018	GARP/TGF-β1	Idiopathic pulmonary fibrosis							–
	Cell therapy	FKC289	BCMA/CD19	Relapsed/refractory primary light-chain amyloidosis							–
				Relapsed/refractory membranous nephropathy							–
	Small molecule	FXS6837 (original project code: XH-S003)	CFB	IgA nephropathy and other glomerular diseases with abnormal complement activation							–
				Paroxysmal nocturnal hemoglobinuria							–
		FXS5626 (original project code: AC-201)	TYK2/JAK1	Non-infectious uveitis							–
				Moderate-to-severe plaque psoriasis							–
		FXS7553 (original project code: XH-S004)	DPP1	Non-cystic fibrosis bronchiectasis (NCFBE)							–
				Chronic obstructive pulmonary disease (COPD)							*Note 6*
Neurodegenerative diseases	Small molecule	Opicapone	COMT	Parkinson syndrome							–
		FXS4983 (original project code:AR1001)	PDE5	Early Alzheimer's disease (AD), including mild cognitive impairment (MCI) and mild Alzheimer's disease (AD)							International multi-center
		Sodium oligomannate capsules	–	Mild-to-moderate Alzheimer's disease, improvement of cognitive function in patients							*Note 7*
CVRM (cardiovascular, renal and metabolism)	Antibody	HLX79 + rituximab injection	Human sialidase fusion protein + CD20	Active glomerulonephritis							–

Therapeutic area	Technology platform	Drug name/code	Target	Indications	IND approved	Phase I	Phase II	Phase III	NDA accepted	Approved for launch	Remarks [Note]
Others	Small molecule	Fortacin Spray (lidocaine and prilocaine aerosol)	–	Primary premature ejaculation in adult men							–
		ET-26 (etomidate hydrochloride injection)	–	Induction of anesthesia and anesthesia for short surgical procedures							–
		OP0595 (Nacubactam) + cefepime or aztreonam	β – lactamase	Treatment of adults infected by aerobic gram-negative bacteria with limited options							–
		Fu Mai Ning (luvometinib tablets, project code: FCN-159)	MEK1/2	Arteriovenous malformations							–
	Others	Fu Ke Shu® (anti-human T-lymphocyte rabbit immunoglobulin)	–	Prevent graft-versus-host disease (GvHD) after the hematopoietic stem cell transplantation							–
		LBP-SHC4	–	Androgenetic alopecia (AGA) (Chinese mainland, U.S.)							–
		HLXTE-HAase02	–	Facilitate the dispersion and absorption of subcutaneously injected or infused drugs							–

Note: Including ① new licensed-in pipelines, ② progress in other regions/countries outside Chinese mainland, and ③ progress occurring after the Reporting Period.

Note 1: HLX903 was a pipeline licensed-in by the Group during the Reporting Period.

Note 2: In July 2026, the Phase I clinical trial of HLX3902 for the treatment of metastatic castration resistant prostate cancer and other advanced solid tumors was initiated in Chinese mainland.

Note 3: The integrated diagnostic and therapeutic radiopharmaceuticals project SRT-007 includes two injections: Ga-[68Ga]PSMA-0057 injection (for diagnosis) and Lu-[177Lu]PSMA-0057 injection (for therapy). Ga-[68Ga]PSMA-0057 injection is a radiopharmaceutical intended for diagnostic use, while Lu-[177Lu]PSMA-0057 injection is a radiopharmaceutical intended for therapeutic use.

Note 4: GR1803 was a pipeline licensed-in by the Group during the Reporting Period.

Note 5: JS005 was a pipeline licensed-in by the Group during the Reporting Period.

Note 6: In August 2026, a Phase II clinical trial of FXS7553 for chronic obstructive pulmonary disease was initiated in Chinese mainland.

Note 7: Sodium oligomannate capsules was a new pipeline addition of the Group during the Reporting Period through the acquisition of Green Valley Pharma; as at the end of the Reporting Period, the drug was at the stage of post-marketing confirmatory clinical trial in Chinese mainland.

Table 3: Major Pipelines for Biosimilars

Therapeutic area	Technology platform	Drug name/code	Targets	Indications	IND approved	Phase I	Phase II	Phase III	NDA accepted	Approved for launch	Remarks
Tumors	Antibody	HLX11	HER2	Neoadjuvant/adjuvant therapy for HER2-positive early BC, metastatic breast cancer	■	■	■	■	■	■	Approved for launch in licensed-out areas of both U.S. and EU, *Note 1*
		HLX13	CTLA-4	Melanoma, hepatocellular carcinoma (HCC), etc.	■	■					International multi-center
		HLX15	CD38	Multiple myeloma (MM)	■	■					–
		HLX15-SC	CD38	Multiple myeloma (MM)	■	■					International multi-center
		HLX17	PD-1	Multiple types of resected solid tumors	■	■					International multi-center
		HLX319	HER2+HER2	Adjuvant/neoadjuvant therapy for HER2-positive early or locally advanced breast cancer, metastatic breast cancer	■	■					–
		HLX18	PD-1	Solid tumors	■						International multi-center, *Note 2*
		HLX05-N	EGFR	Metastatic colorectal cancer (Chinese mainland, U.S.)	■						*Note 3*
CVRM (cardiovascular, renal and metabolism)	Others	HLX14	RANKL	Osteoporosis (OP), skeletal-related events, etc.	■	■	■	■	■		Approved for launch in licensed-out areas of U.S., EU and Canada, *Note 4*
		Mixed protamine zinc recombinant insulin lispro injection (25R)	–	Diabetes	■	■	■	■	■		–
		Semaglutide injection	GLP-1	Diabetes	■	■	■	■	■		–
		Liraglutide injection	GLP-1	Diabetes	■	■	■	■			–
		Insulin degludec injection	–	Diabetes	■	■	■	■			–

Note 1: Among these, during the Reporting Period, HLX11 was approved for launch in Chinese mainland and the EU, covering all indications for which the reference drug has been approved in these respective local markets.

Note 2: In July 2026, a Phase I clinical trial of HLX18 for solid tumors was initiated in Chinese mainland.

Note 3: In July 2026, a Phase I clinical trial of HLX05-N for metastatic colorectal cancer was initiated in Chinese mainland.

Note 4: Among these, during the Reporting Period, HLX14 was approved for launch in Canada, covering all indications for which the reference drug has been approved in the local market.

Table 4: Major Pipelines for Vaccines

Drug name/code	Indications	IND approved	Phase I	Phase II	Phase III	NDA accepted	Approved for launch	Remarks
13-valent pneumococcal polysaccharide conjugate vaccine	Prevention of pneumococcal related diseases							–
Rabies vaccine (human diploid cells) for human use (freeze-dried)	Rabies prophylaxis							–
24-valent pneumococcal polysaccharide conjugate vaccine	Prevention of pneumococcal related diseases							–
23-valent pneumococcal polysaccharide vaccine	Prevention of pneumococcal related diseases							–

In July 2026, the National Essential Medicines List (2026 Edition)《國家基本藥品目錄(2026年版)》was released (officially taking effect on 1 September 2026). Four products with six specifications independently developed and produced by the Group, namely Han Qu You (trastuzumab for injection), Han Bei Tai (bevacizumab injection), Han Li Kang (rituximab injection), and Han Da Yuan (adalimumab injection), were included in the list, covering the therapeutic areas of anti-tumor and immunology and inflammation. The inclusion will effectively enhance the accessibility of these biologics across medical institutions at all levels nationwide to benefit a wider range of patients.

As at the date of this announcement, a total of 53 products of the Group that had passed or were deemed to have passed the consistency evaluation of generic drugs were selected in the total 12 batches of national centralized drug procurement and the insulin specialty successive procurement bidding. For the existing products included in centralized drug procurement, the Group has leveraged the advantages of multi-channel marketing and lean production to strengthen the life cycle management of the centralized drug procurement products while trading price for volume.

Production integration and streamlined operations: building a manufacturing system with international competitiveness

In order to further improve the competitiveness of the production system of the pharmaceutical manufacturing business, enhance operational efficiency and support the implementation of the internationalization strategy, the Group continued to deepen the resource integration and lean transformation at the production end, and systematically built an agile, efficient and compliant global supply chain system by establishing large-scale production centers, deploying production lines with high technical barriers, and benchmarking international quality standards.

(1) ***Capacity integration and intensive layout: establishment of core production centers***

The Group continued to advance intensive and regional integration at the production end to improve operational efficiency and strengthen cost advantages through economies of scale.

– Regional production and vertical integration: relying on the two preparations production bases and three API bases, the established medicines manufacturing and supply business in China has formed large-scale regional manufacturing cores, enhancing the overall production efficiency. In particular, three APIs bases were successively put into production or entered into stable operation, realizing the full-chain internal integration from APIs to preparations, and strengthening supply chain resilience and cost control capabilities.

– Global production capacity layout: as at the end of the Reporting Period, the total built capacity of the biologics production base of Shanghai Henlius, a subsidiary, was 84,000 liters, of which 48,000 liters was in commercial operation, and the base has normalized supply to the global market with distribution covering markets including China, Europe, Canada, Latin America, Southeast Asia and India. The injectable production lines located in India and Europe of Gland Pharma, a subsidiary, continued to supply markets such as the U.S. and Europe. In addition, during the Reporting Period, the Phase I project of the Cote d'Ivoire park entered the stage of verification and product transfer, laying a solid foundation for the subsequent localized manufacturing and establishment of supply networks in Africa.

(2) ***Construction of high-technical-barrier production lines: enhancement of complex formulations manufacturing capabilities***

The Group actively deployed in the fields of complex formulations and special preparations. Several high-value-added production lines have entered into the commissioning or validation phases, continuously raising the technical and manufacturing thresholds and the added-value of the products.

– Production lines commissioned or in trial production phase during the Reporting Period:

  ■ Fosun Pharma (Xuzhou) (Preparation Base): the construction of the solid dispersion and OEB4 oral solid preparation production line has been completed, entering the transfer and production validation stage for relevant products.

- Carelife Pharma (API Base): the construction of the polypeptide production line has been completed, and the trial production and transfer of relevant products have been commenced. The sterile API production line has entered the validation and trial production phase.

– Production lines entering validation phase during the Reporting Period:

- Fosun Wanbang's long-acting injection production line has entered the product validation stage.

(3) ***International quality standard certification: acceleration of global deployment for preparations***

The Group continued to benchmark against the standards of major international regulatory markets, and comprehensively advanced the international certification of its quality management system, laying a compliant foundation for product export. As at the end of the Reporting Period, the pharmaceutical manufacturing segment had 65 workshops/production lines that had passed GMP certifications in major overseas markets including the U.S., EU and Japan as well as WHO PQ certifications, while steadily advancing its layout in emerging markets.

– Progress in certification of production lines in emerging markets during the Reporting Period:

- Suzhou Erye: rivaroxaban tablets passed the Nigeria GMP compliance inspection.

- Shandong Erye: oxacillin sodium passed the Brazil GMP compliance inspection.

- Guilin Pharma: a total of 26 product specifications across injections and tablets, including artesunate for injection and sulfadoxine and pyrimethamine + amodiaquine hydrochloride dispersible tablets, passed the Nigeria GMP compliance inspection.

- Shanghai Henlius: HETRONIFLY (100mg/10ml) passed the Turkey GMP compliance inspection.

2. Medical Devices and Medical Diagnosis

The medical devices and medical diagnosis business initially established core businesses focused on medical cosmetology, respiratory health, professional medical devices and in vitro diagnosis. During the Reporting Period, the medical devices and medical diagnosis business recorded revenue of RMB1,859 million, representing a period-on-period decrease of 4.81%; the segment result was a loss of RMB128 million, and the segment profit/loss was a loss of RMB22 million. In the first half of 2026, the medical cosmetology and respiratory health business experienced phased pressure, mainly due to intensified competition in the North American market and increased phased investments in strategic new products, among other factors. During the Reporting Period, key progresses in the medical devices and medical diagnostics business include:

– ***Medical Cosmetology***

- Energy-based Equipment: due to sluggish demand in the North American market, revenue from energy-based equipment decreased by 3% period-on-period. Excluding the North American region, Sisram Medical's revenue from international market overall maintained growth, with core product lines (Soprano, Hybrid and Alma Harmony) performing steadily.

- Injectable Fillers: DAXXIFY was commercially launched in the Chinese market with increased phased market investments; Profhilo (a new-generation sodium hyaluronic complex) maintained a growing demand trend in Thailand; and Hallura (an innovative BDDE-free hyaluronic acid product) continued its expansion in the Israeli market.

– ***Respiratory Health***

- Affected by medical insurance policies, the growth of Breas ventilator products in the U.S. market experienced phased pressure; businesses in other regions remained generally steady, achieving rapid growth in penetration rates in key markets such as Japan and Europe. Meanwhile, the Group continuously increased R&D investment to build a robust pipeline and focused on market access, expanding its business to nearly 60 countries and regions worldwide. Breas Apto, a new mask product for professional respiratory therapy was launched in Europe, realizing the strategy of leveraging Chinese manufacturing capabilities to serve the global market.

– ***Professional Medical Devices***

- Fosun Insightec: in the first half of 2026, the V2 new model of the "MRgFUS" brain therapy system was approved for registration in Chinese mainland, and the expansion of new indications has been steadily progressing. During the Reporting Period, two additional units of "MRgFUS" were sold in Chinese mainland, one of which has completed installation. A cumulative total of over 200 procedures have been performed, and the product's clinical value and recognition in the domestic market continue to enhance.

- Intuitive Fosun (the associated company): during the Reporting Period, 6 units of "Da Vinci Surgical Robots" were installed in Chinese mainland, Hong Kong and Macau. "Da Vinci 5 – the new-generation surgical robot" completed its first installation in Hong Kong, and was included in the NMPA's special review procedure for innovative medical devices, which is conducive to accelerating the progress of subsequent registration and regulatory approval.

– ***Medical Diagnosis***

- The self-developed STD urine nucleic acid quad assay was approved for launch, representing the first national quad-nucleic acid assay solution for STDs (Ureaplasma urealyticum/Chlamydia trachomatis/Neisseria gonorrhoeae/ Mycoplasma genitalium nucleic acid detection kit, fluorescent PCR method). It is lyophilized and easy to use, and has been applied in clinical practice across multiple tertiary hospitals.

- The high-speed direct-connected line F-A6200 was newly launched, empowering laboratory automation upgrades with a more compact size, more flexible configuration and smoother operational logic.

3. Healthcare Services

During the Reporting Period, the revenue from the healthcare services business amounted to RMB3,735 million, representing a period-on-period increase of 4.07%. Segment results for the period were a loss of RMB86 million, and the segment profit/loss was a loss of RMB207 million. The factors influencing the changes in results include breakthroughs achieved in the international operations of the integrated healthcare service business, positive trends in active consumption, and cost reduction and efficiency improvement through supply chain integration. However, the rehabilitation specialty chain business is still in a phase of concentrated business ramp-up and there is still a need for relevant personnel and operational capability deployment, leading to an expansion in losses for the current period.

(1) ***Healthcare services business focusing on integrated medical institution***

The healthcare services business, mainly consisting of integrated medical institutions, centers on the Greater Bay Area and builds an integrated online-and-offline healthcare service platform with featured specialties such as oncology and orthopedics. With years of cultivation, Fosun Health, a subsidiary, continued to enhance the level of medical disciplines, promoted the integrated operation of medical institutions as well as the integration of online and offline services, extended its reach to primary-level healthcare, provided multi-level and differentiated services, and innovatively built a full-lifecycle health management system. During the Reporting Period, the continued focus on core operations resulted in improved core profitability.

– *Layout and development: focusing on high-quality medical care and further advancing integration practices*

- Extensive and professional medical network: centered on the Greater Bay Area and the Yangtze River Delta, medical institutions including general hospitals, specialized hospitals and clinics are operated in the Beijing-Tianjin-Hebei region, Central China and the Sichuan-Chongqing area. As at the end of the Reporting Period, Fosun Health controlled 18 medical institutions, such as general hospitals, specialized hospitals and clinics. The medical institutions controlled by Fosun Health had a total of 6,470 authorized beds, and held 8 internet hospital licenses.

- Continued investment in key specialties: the core of medical care has been continuously enhanced through the construction of discipline systems, enhancement of diagnosis and treatment capabilities, and the introduction and iteration of innovative medical technologies. During the Reporting Period, the Orthopedics Department of Foshan Fosun Chancheng Hospital was approved as a "2025 Guangdong Provincial Key Clinical Specialty Construction Project;" and Chongqing Shinrong Plastic Surgery Hospital was designated as an affiliated hospital of China Pharmaceutical University, marking the first tertiary-level plastic surgery hospital in Chongqing.

- Deepening the integration practice of "Chief Hospital in the Greater Bay Area": advantages of group operation were leveraged in terms of regional medical resources coordination, medical network expansion, discipline construction, financial management, smart healthcare, brand strategy and supply chain efficiency, and regional integration operation strategy was deepened. Several medical institutions are designated hospitals for the "Hong Kong and Macau Medicine and Equipment Connect", and nearly 100 innovative international drugs and medical devices were introduced cumulatively as at the end of the Reporting Period.

– *Innovation and development: deepening innovative business models and expanding market opportunities for strategic businesses*

- Accelerating the international strategic layout: during the Reporting Period, Fosun Health continued to advance its internationalization. It has actively expanded into markets such as Indonesia, Bangladesh, Mongolia, Hong Kong and Macau regions, and built an open, stable and professional international medical collaboration network. In addition, the standalone medical building of the International Medical Center of Foshan Fosun Chancheng Hospital was newly put into operation, with a planned capacity of 100 beds, establishing a full-process international medical service closed-loop integrating outpatient care, inpatient care, physical examinations and rehabilitation.

- Promoting two-way empowerment between healthcare and insurance: during the Reporting Period, it continued to improve the commercial insurance operation system. Leveraging the specialty departments and cutting-edge medical technologies, it created diversified and customized innovative insurance payment solutions. As at the end of the Reporting Period, Fosun Health's controlled medical institutions had accumulatively signed agreements with over 55 domestic and international insurance institutions, and Foshan Fosun Chancheng Hospital, a controlled medical institution, was selected among the first batch of 25 pilot hospitals for international medical services in Guangdong Province.

(2) ***Rehabilitation specialty chain business***

The rehabilitation specialty chain business promotes high-quality and steady development through the "multiple locations in one city" investment and operation management model. During the Reporting Period, the Group continued to deepen its strategic deployment of the rehabilitation specialty business, and its subsidiary Jianjia Healthcare steadily expanded by focusing on core markets such as municipalities directly under the central government, new first-tier cities and provincial capitals through the "multiple locations in one city" investment and operation management model, thereby driving the high-quality development of the rehabilitation specialty chain business.

– *Refining chain network layout and deepening the lean operation system*

- Medical network layout: as at the end of the Reporting Period, the rehabilitation specialty chain business controlled and operated 24 rehabilitation hospitals, further solidifying its nationwide chain layout. As the business gradually matures, economies of scale and operational efficiencies will be progressively unleashed.

- Lean and asset-light operations: the standardized 3.0 model for rehabilitation hospitals was continuously iterated, focusing on refined and specialized empowerment for key regions and key projects. The asset-light output model was steadily explored and expanded to enhance business radiation capacity and diversified profitability.

– *Focusing on core specialty construction to build technical and talent barriers*

- Deepening the specialty matrix: building upon the three strategic sub-specialties of neurological rehabilitation, critical care rehabilitation and musculoskeletal rehabilitation, it further consolidated the construction of the "top ten specialized rehabilitation technology bases," developed featured techniques such as dysphagia rehabilitation, respiratory rehabilitation, pain rehabilitation, wound rehabilitation and motor dysfunction rehabilitation, and continuously deepened clinical service levels.

- Strengthening technology-driven development: it introduced cutting-edge equipment such as upper and lower limb intelligent rehabilitation devices and exoskeleton robots, and continuously advanced core new rehabilitation technologies; meanwhile, it brought in top-tier medical and management experts in the industry, systematically advanced multi-disciplinary talent teaching and training, continuously improved professional talent pipeline construction, and consolidated its leading clinical specialty advantages.

– *Promoting payment model innovation and expanding the commercial insurance cooperation ecosystem*

- Establishing a diversified commercial insurance payment network with deep coverage of mainstream market commercial insurance institutions and payment products, thereby constructing a multi-tiered commercial insurance network; meanwhile, building a commercial insurance service assurance system to ensure the efficient and compliant operation of payment channels.

– *Accelerating digital upgrading and comprehensively empowering healthcare and management with AI*

- Deploying the AI rehabilitation butler to achieve all-scenario (including medical consultation, medical insurance and appointments) and 24/7 online response, optimizing the patient care experience. Through the clinical quality control AI system, decisions have been made; through the medical insurance AI intelligent audit system, medical insurance compliance has been gradually enhanced; and the AI-assisted image diagnosis system covering various common diseases has improved clinical diagnostic efficiency.

4. Pharmaceutical Distribution and Retail

During the Reporting Period, facing the reform trend of the industry landscape and the regulatory environment, Sinopharm, an associated company, recorded the operating income of RMB282.80 billion, the net profit of RMB5.18 billion and the net profit attributable to owners of the parent company of RMB3.404 billion, representing a period-on-period decrease of 1.13%, 2.95% and 1.79%, respectively.

During the Reporting Period, affected by multiple factors such as volume-based procurement, red-and-yellow label price governance, and medical insurance cost control, Sinopharm's pharmaceutical distribution segment recorded an operating income of RMB215.496 billion, representing a period-on-period decrease of 1.39%. Meanwhile, in the first half of 2026, Sinopharm firmly seized the development opportunities of national negotiated varieties and innovative drugs, and vigorously increased market share. The sales of national negotiated varieties and innovative drugs recorded a rapid period-on-period growth, and according to management caliber statistics, the growth rates reached 27% and 30% respectively, forming a structural complement to the decline in sales of volume-based procurement varieties and effectively hedging the downward pressure on overall revenue.

During the Reporting Period, Sinopharm's medical device distribution segment focused on building medical terminal service capabilities, improved its full-process compliance management and control level, promoted the optimization and upgrading of the business structure, and steadily improved the operational quality and efficiency. In the first half of 2026, Sinopharm's medical device distribution segment recorded an operating income of RMB56.854 billion, representing a slight period-on-period decrease of 0.35%.

During the Reporting Period, Sinopharm's retail pharmacy segment continued its previous rapid growth momentum, achieving sales revenue of RMB18.635 billion, representing a period-on-period increase of 8.58%. Of this total, affected by factors such as the optimization and adjustment of store structure as well as the overall market environment including medical insurance cost control and price governance, the sales revenue of the Guoda Drugstore system decreased period-on-period; the specialty pharmacy system deeply grasped the industry opportunities of expanded prescription circulation and accelerated pace of out-of-hospital commercialization of innovative drugs, vigorously undertook prescription traffic such as innovative drugs, and maintained steady growth in sales revenue. As at the end of the Reporting Period, the number of stores of Sinopharm's Guoda Drugstore was 7,975, of which the number of stores of specialty pharmacy was 1,440.

III. Core Competence Analysis

1. Advantages in R&D and Innovation: An Open-ended and Systematic Global Innovation Sourcing Capability

Focusing on unmet clinical needs, the Group continues to concentrate on core therapeutic areas and strengthen its layout in cutting-edge technologies, accelerating the implementation of innovation outcomes and realizing global value.

- Focus on core segments: continuously focusing on three major areas including oncology, immunology and inflammation, neurodegenerative diseases.

- Deployment in cutting-edge technologies: consolidating core platforms across antibodies and ADC and new-generation small molecules, while actively building capabilities in cutting-edge technologies such as radiopharmaceuticals, small nucleic acids, peptides and cell therapy.

- Diversified cooperation models: integrating models such as independent R&D, licensing-in and industrial fund incubation to form a mode of "independent R&D + external innovation", while balancing self-control of core pipelines with early deployment of groundbreaking advancements, so as to build a highly resilient innovation ecosystem.

- Global transformation capability: leveraging proficiency in simultaneous clinical and registration pathways in China, the U.S., Europe, Australia, etc., to accelerate the global launch of innovation outcomes and maximize product lifecycle value.

2. Advantages in Internationalized Production and Operations: A Flexible Supply Chain Integrating APIs and Preparations

The Group's manufacturing advantages have been upgraded into a strength integrating internationally compliant quality systems, vertically integrated cost advantages, and global production capacity.

- International quality certifications: as at the end of the Reporting Period, a total of 65 workshops/production lines in the pharmaceutical manufacturing segment had passed GMP certifications in major overseas markets including the U.S., EU and Japan, as well as WHO PQ certifications, including 20 within Chinese mainland and 45 overseas.

– Vertical integration: the established medicines manufacturing and supply business has built two preparations centers and three APIs bases domestically, covering full industry chain from intermediates to preparations, demonstrating triple core values of controllable costs, R&D synergy and quality traceability.

– Global production capacity: biologics manufacturing bases have normalized supply to the global market, with distribution covering markets including China, Europe, Canada, Latin America, Southeast Asia, India. As at the end of the Reporting Period, a total of 84,000 liters production capacity had been built, of which 48,000 liters had been commissioned for commercial operation. Gland Pharma possesses global supply capabilities as well. In addition, in emerging markets such as Africa and the Middle East, the Group is actively advancing local production capacity deployment.

3. Advantages in Commercialization System: Globally Integrated Value Transformation Capability

The Group's core commercialization capability lies in efficiently transforming clinical value into global commercial value through the "Pharmaceuticals + Medical Devices" dual-engine drive and the deep integration of globalization and localization.

– Global marketing network:

  ■ Pharmaceuticals: leveraging overseas subsidiaries in the U.S., Europe, Africa, etc., the Group has established localized academic promotion and market access capabilities, achieving an upgrade from "product exporting" to "capability exporting", with innovative products on sale in nearly 90 countries and regions around the world.

  ■ Medical devices: Sisram Medical, a subsidiary, combines "digitalization + direct sales and distribution", and has established 12 direct-sales offices globally with marketing network spanning over 110 countries and regions, securing a global leadership position in the medical aesthetics field; Breas, a subsidiary, has consolidated its international competitiveness in the respiratory therapy field.

– Integrated diagnosis and therapy: upgrading from "single product sales" to "comprehensive solutions", the Group has progressively built an ecological closed loop of "diagnosis + treatment" in the field of neurodegenerative diseases, and continuously advanced the integration of diagnosis and therapy in the oncology field.

– Product portfolio optimization: continuously increasing the sales proportion of high-value Innovative Drugs.

IV. Major Operations in the Reporting Period

(I) *Analysis on Principal Operations*

1. Analysis of Changes in Relevant Items of Financial Statements

Unit: million Currency: RMB

Items	Amount for the period	Amount for the corresponding period of last year	Period-on-period change
Revenue	20,377	19,426	4.90%
Cost of sales	10,288	10,123	1.63%
Selling and distribution expenses[Note 1]	4,418	4,211	4.92%
Administrative expenses[Note 2]	2,293	2,124	7.96%
R&D expenses[Note 3]	2,087	1,717	21.55%
Finance costs[Note 4]	607	653	-7.04%
Other income	155	210	-26.19%
Other gains[Note 5]	633	1,164	-45.62%
Other expenses[Note 6]	127	317	-59.94%
Share of profits and losses of associates	1,144	934	22.48%
Net cash flow generated from operating activities	2,424	2,134	13.59%
Net cash flow generated from investing activities[Note 7]	-4,428	-860	-414.88%
Net cash flow generated from financing activities[Note 8]	2,676	-1,460	283.29%

Note 1: During the Reporting Period, the selling expense ratio was 21.68%, which remained basically flat as compared with the corresponding period of last year. Gross profit margin minus selling expense ratio was 27.83%, representing a period-on-period increase of 1.62 percentage points.

Note 2: During the Reporting Period, the administrative expense ratio was 11.25%, representing a period-on-period increase of 0.32 percentage point. Excluding the impact of equity incentive compensation expenses on the same basis, the administrative expense ratio was 10.30%, representing a period-on-period decrease of 0.53 percentage point.

Note 3: During the Reporting Period, R&D expenses increased by 21.55% period-on-period, which was mainly due to the Group's accelerated deployment of early-stage R&D platforms and increased investments in innovative drug R&D.

Note 4: During the Reporting Period, finance costs decreased by 7.04% period-on-period, which was mainly due to the optimization of financing costs for interest-bearing liabilities.

Note 5: It was mainly due to the combined effect of changes in fair value of financial assets held, clearance of receivables and payables not required to be paid, and disposal of non-core assets such as United Family Healthcare*Note* in the previous period.

Note 6: It was mainly due to the provision for impairment of long-term equity investments in the corresponding period of last year.

Note 7: It was mainly due to the combined effect of cash inflows from disposal of non-core assets such as United Family Healthcare in the corresponding period of last year and other new investments made during the period.

Note 8: It was mainly due to the combined effect of increase in the scale of interest-bearing liabilities and increase in equity financing during the period.

2. R&D expenditure

(1) *R&D expenditure*

Unit: million Currency: RMB

R&D expenditure expensed for the period	2,087
R&D expenditure capitalized for the period	1,160
Total R&D expenditure	3,247
Total R&D expenditure as a percentage of revenue (%)	15.88
R&D expenditure in the pharmaceutical manufacturing business as a percentage of the revenue from the pharmaceutical manufacturing business (%)	20.60
Percentage of R&D expenditure capitalized (%)	35.73

Note: Representing the disposal of the remaining equity interest in Unicorn II Holdings Limited, whose main assets are the "United Family Healthcare" hospitals and clinics held and operated through its subsidiary, the same below.

(2) *Descriptions*

During the Reporting Period, the Group's total R&D expenditure amounted to RMB3,247 million, representing a period-on-period increase of 25.66%; of which R&D expenses amounted to RMB2,087 million, representing a period-on-period increase of 21.55%. Total R&D expenditure in the pharmaceutical manufacturing business amounted to RMB3,046 million, representing a period-on-period increase of 32.72%; of which R&D expenses amounted to RMB1,898 million, representing a period-on-period increase of 29.20%. R&D expenditure related to Innovative Drugs reached RMB2,650 million, representing a period-on-period increase of 48.38%; R&D expenditure in Innovative Drugs accounted for 81.61% of the Group's total R&D expenditure, representing a period-on-period increase of 12.50 percentage points, and accounted for 87.00% of the pharmaceutical manufacturing business's R&D expenditure, representing a period-on-period increase of 9.18 percentage points. It mainly covered investments in pipelines such as HLX43, HLX22, GR1803 and FXR0906, as well as technology platforms including new-generation small molecule drugs and radiopharmaceuticals, with resources continuously tilting towards innovative drugs.

(II) *Segment and Regional Operations*

Principal Operations by Segments, Products and Geographical Locations

Unit: million Currency: RMB

	Principal operations by segments					
By segments	Revenue	Cost of sales	Gross profit margin	Period-on-period change in revenue	Period-on-period change in cost of sales	Period-on-period change in gross profit margin
Pharmaceutical manufacturing	14,727	6,239	57.64%	6.59%	-0.48%	Increase of 3.01 percentage points
Medical devices and medical diagnosis	1,859	932	49.87%	-4.81%	1.30%	Decrease of 3.02 percentage points
Healthcare services	3,735	3,067	17.88%	4.07%	6.57%	Decrease of 1.93 percentage points

Principal operations by products

By products	Revenue	Cost of sales	Gross profit margin	Period-on-period change in revenue	Period-on-period change in cost of sales	Period-on-period change in gross profit margin
Major products of tumor and immune modulation	4,632	1,065	77.01%	7.37%	10.02%	Decrease of 0.55 percentage point
Major products of anti-infection	1,870	638	65.88%	12.92%	7.77%	Increase of 1.63 percentage points
Major products of metabolism and alimentary system	1,405	360	74.38%	7.58%	-0.28%	Increase of 2.02 percentage points
Major products of cardiovascular system	960	417	56.56%	3.67%	-1.88%	Increase of 2.46 percentage points
Major products of central nervous system	480	75	84.38%	-2.44%	5.63%	Decrease of 1.19 percentage points
Major products of APIs and intermediate products	549	435	20.77%	-9.56%	-9.00%	Decrease of 0.48 percentage point

Principal operations by geographical locations

By geographical locations	Revenue	Cost of sales	Gross profit margin	Period-on-period change in revenue	Period-on-period change in cost of sales	Period-on-period change in gross profit margin
Chinese mainland	13,998	6,902	50.69%	0.36%	0.86%	Decrease of 0.25 percentage point
Regions outside Chinese mainland and other countries	6,379	3,386	46.92%	16.45%	3.23%	Increase of 6.80 percentage points

(III) *Analysis on Subsidiaries and Investees*

1. Operation and Results of Major Subsidiaries of the Group

(1) Operation and Results of Major Subsidiaries

Unit: million Currency: RMB

Name of subsidiary	Major business	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
Shanghai Henlius *(Note 1)*	Pharmaceutical R&D and manufacturing	545	13,096	4,539	3,588	511	430
Yao Pharma	Pharmaceutical R&D and manufacturing	197	10,225	7,876	2,238	570	482
Gland Pharma *(Note 2)*	Pharmaceutical R&D and manufacturing	NA	10,078	8,290	2,604	542	392
Fosun Wanbang	Pharmaceutical R&D and manufacturing	480	8,947	5,148	3,312	295	228

Note: The above data included valuation appreciation and amortization of valuation appreciation.

Note 1: The data for Shanghai Henlius is prepared in accordance with International Financial Reporting Standards.

Note 2: The data for Gland Pharma is prepared in accordance with Indian Generally Accepted Accounting Principles.

(2) Status of Other Major Subsidiaries

Unit: million Currency: RMB

Name of subsidiary	Major business	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
Sisram Medical *(Note 1)*	Medical devices R&D and manufacturing	NA	4,604	3,414	1,184	27	7
Foshan Fosun Chancheng Hospital *(Note 2)*	Healthcare services	50	4,111	2,115	1,226	65	52

Note 1: The data for Sisram Medical is prepared in accordance with International Financial Reporting Standards.

Note 2: The data for Foshan Fosun Chancheng Hospital included valuation appreciation and amortization of valuation appreciation.

2. Operation and Results of Investee Companies whose Net Profit and Investment Income Contributing More Than 10% of the Group's Net Profit

Unit: million Currency: RMB

Name of subsidiary	Major business	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
Sinopharm Industrial	Investment and asset management	100	405,454	137,707	282,800	6,907	5,172

3. Major Acquisition and Disposal of Subsidiaries during the Reporting Period

(1) Acquisition of Subsidiaries during the Reporting Period:

Company Name	Acquired through	Date of acquisition
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.* (綠谷(上海)醫藥科技有限公司)	Equity acquisition	24 March 2026

(2) Disposal of Subsidiaries during the Reporting Period:

Company Name	Disposed through	Date of disposal
Shenyang Wanbang Tiansheng Biological Technology Co., Ltd.* (瀋陽萬邦天晟生物科技有限公司)	Equity transfer	28 January 2026
Ningbo Jiangbei Xingjian Lanting Nursing Home Co., Ltd.* (寧波江北星健蘭亭護理院有限公司)	Equity transfer	14 February 2026
Huaiyin Medical Instruments Co., Ltd.* (淮陰醫療器械有限公司)	Equity transfer	18 May 2026
Shandong Weifeng Biological Technology Co., Ltd.* (山東蔚楓生物科技有限公司)	Equity transfer	27 May 2026

Company Name	Disposed through	Date of disposal
Jinan Fujian Xingweilai Medical Investment Management Partnership (Limited Partnership)* (濟南復健星未來醫療投資管理合夥企業(有限合夥))	Equity transfer	29 June 2026

(IV) *Employees and Remuneration Policies*

As at the end of the Reporting Period, the Group had a total of 40,684 employees. The employees' remuneration policies of the Group are formulated on the basis of their performance, work experience and salary level prevailing in the market.

(V) *Assets and liabilities analysis*

As at the end of the Reporting Period, the gearing ratio of the Group, calculated as total interest-bearing bank and other borrowings over total assets, was 28.55%, as compared to 27.46% as at 31 December 2025.

V. Outlook for Operations in the Second Half of 2026

In the second half of 2026, the Group will maintain its focus on clinical needs, target the global market, uphold being innovation-driven, accelerate internationalization, and actively build an AI+ healthcare ecosystem. In terms of innovative R&D, the Group will focus on core business segments, vigorously develop strategic products, and enhance R&D efficiency while strengthening its technological platform capabilities. In terms of global operations, the Group will build a global commercialization system, optimize the layout of the global supply chain, and actively promote the internal output and external introduction of high-value pipelines. In addition, the Group will leverage AI tools to continuously enhance R&D efficiency and operational quality. In order to achieve the above operating objectives, specific strategies and actions include:

Pharmaceutical Manufacturing

In terms of the innovative drug business, the Group will focus on the three core therapeutic areas of oncology (solid tumors and hematologic tumors), immunology and inflammation, neurodegenerative diseases, and continue enriching product portfolio while simultaneously expanding into CVRM (cardiovascular, renal and metabolism), anti-infections and rare diseases, among others. While consolidating the core technology platforms of antibodies and ADC, and new-generation small molecule drugs, the Group will deploy cutting-edge technologies such as radiopharmaceuticals, small nucleic acids, peptides, and cell therapies to capture global innovation opportunities. In the second half of 2026, key clinical data readouts are expected gradually for innovative pipelines such as AR1001, FXS7553, FXS6837, SRT-007, HLX10 (the bridging trial in U.S.) and HLX43. Moreover, part of these clinical data is planned to be presented at major global industry and academic conferences, including the World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) Congress.

In terms of the established medicines manufacturing and supply business, in R&D, the Group will establish R&D projects for improved new drugs as well as difficult generic drugs and differentiated products, etc., efficiently promote the development of pipeline products, and make deployment in high-end/complex formulations such as in situ gels, minitablets, oral fast dissolving film, inhalation and sustained and controlled release, to form a differentiated R&D layout. Among these, the abbreviated new drug application (ANDA) has been submitted for 3 complex formulations and 3 ready-to-use (RTU) infusion bag products of Gland Pharma, a subsidiary. In addition, at the beginning of August 2026, Gland Pharma entered into a strategic manufacturing and supply agreement with a global pharmaceutical company. The product portfolio covers both oncology and non-oncology fields, with dosage forms including vials, lyophilized powder for injection, ampoules, and pre-filled syringes (PFS), covering both conventional and complex injectable formulations. Once all products are commercialized, the annualized revenue potential is expected to be approximately USD90 million to USD100 million. In terms of operation, the Group will consolidate and plan the industrial layout, strengthen the integration of APIs and preparations, deploy characteristic APIs and emerging technology platforms, so as to build a competitive edge of "technology-quality-cost". Meanwhile, it will continue to strengthen the construction of international registration and marketing system of APIs, comprehensively improve operational efficiency, develop leadership in terms of cost, and focus on promoting the integration and international collaboration of the industry.

In terms of the vaccines business, the Group continues to enrich the product portfolio of bacterial vaccines, viral vaccines and emerging vaccine technology platforms, actively promotes the clinical trials of self-developed 13-valent pneumococcal conjugate vaccine (multivalent combinations), rabies vaccine (human diploid cells) for human use (freeze dried), 23-valent pneumococcal polysaccharide vaccine and 24-valent pneumococcal polysaccharide conjugate vaccine, and steadily advances the R&D of strategic vaccine products in its pipeline.

Medical Devices and Medical Diagnosis

In the second half of 2026, with emphasis on being innovation-driven and deepening globalization, the medical devices and medical diagnosis business is committed to deepening industrial focus and accelerating the breakthroughs by focusing on the two main targets of efficient asset operation and profitability enhancement. Through efficient integration, the Group will advance divisional streamlined transformation through optimization of assets structure and asset allocation, so as to boost operational efficiency and profitability. The Group will enhance value-based marketing, comprehensively strengthen marketing, medical and market access capabilities, and accelerate value conversion from product to market. Meanwhile, the Group will deepen global operations, improve operational quality of overseas enterprises, and advance the two-way empowerment between domestic enterprises' overseas expansion and overseas enterprises' localization, so as to establish a globally coordinated framework.

Healthcare Services

In the second half of 2026, based on the consolidation of its existing advantageous areas, the healthcare services business centered on integrated medical institutions, will focus on providing high-quality medical services, continuously enhance clinical capabilities, and drive innovation and implementation of medical technologies. The Group will develop proactive health management services and improve product-based healthcare systems. The Group will also expand and explore international market growth opportunities and progressively advance regional expansion. Meanwhile, the Group will deepen collaborations with commercial insurance institutions to expand incremental payment models.

In the second half of 2026, the rehabilitation specialty business will comprehensively deepen its strategic transformation toward "high-quality sustainable development." Building upon the proactive promotion of the "asset-light expansion and operation" model, the Group will fully drive the development of the core rehabilitation assessment system and the rollout of demonstration bases for "Top 10 Specialty Rehabilitation Technologies." Meanwhile, the Group will extend rehabilitation interventions from in-hospital sub-acute recovery phases to out-of-hospital plateau phases, community care, and home care scenarios. The Group will also continue to deepen innovative payment partnerships with major commercial insurance institutions, further extending its reach into broader rehabilitation consumption domains, and to seek new performance growth opportunities through innovative specialty rehabilitation programs.

VI. Potential Risks

(I) *Industry policy adjustments*

The medical healthcare industry, being an important area of developing new quality productive forces, is one of the industries most affected by national policies. With the in-depth advancement of the reform of "Three Medical Linkages", namely medical services, medical insurance and medical healthcare, profound changes are taking place in the industry landscape, leading to the innovative transformation, industry consolidation and transformation in business models becoming a matter of great urgency. In 2026, the continuous deepening of centralized volume-based procurement for pharmaceuticals and high-value medical consumables, while alleviating patient financial burdens, has accelerated the industry's drive to break out of homogenized competition and transform toward differentiated, high-quality innovation.

In the field of medical devices and medical diagnosis, the sixth batch of national centralized volume-based procurement for high-value medical consumables was implemented, with "anti-cutthroat competition" rules and innovation-leaning policies being advanced simultaneously, balancing room for technological innovation under cost-containment targets and accelerating the localization process of high-value medical equipment; sub-sectors with large scale and high localization rates entered a phase of trading price for volume, while enterprises mastering key bottleneck technologies embraced a window of opportunity for differentiated development; the policies encourage enterprises to integrate resources and complement each other's advantages, which intensifies the support for the innovation of high-end medical devices and encourages enterprises to achieve technological breakthroughs, and continuously improve the technological levels of clinical products. Equipment upgrade, centralized procurement of medical consumables in bulk and localized production will also bring about a significant change to the industry.

In the field of healthcare services, socially organized medical institutions have to conduct more strategic and diversified deliberations on how to strengthen collaboration with dominant public healthcare providers while pursuing differentiated development patterns and collaborative expansion. Meanwhile, the growing trend of an aging population and increasing demand for chronic disease management continue to drive the expansion of the market scale, as the healthcare service system profoundly evolves from a single offline model toward online-offline integrated and intelligent solutions. The integrated application of AI technology across various healthcare scenarios is accelerating implementation, driving the healthcare service industry to upgrade toward high-quality and refined development.

In this regard, the Group will closely monitor and analyze the policy trends of related industries, keep abreast of the development trends of the industry and continuously improve business management mechanisms, so as to fully reduce the operating risks caused by policy changes.

(II) ***Market competition risks***

With the ongoing normalization of the centralized procurement of drugs and medical consumables, coupled with continued policy support for innovative drugs, the pharmaceutical industry is undergoing profound changes. On the one hand, the innovative drug sector faces risks arising from changes in domestic policies and market conditions; on the other hand, it is confronted with intense competition from both multinational and domestic innovative drug enterprises. In addition, any mismatch between drug R&D and clinical needs, or sluggish sales following market launch due to intensified competition or other factors, may affect the recovery of initial investment and the realization of economic benefits, thereby adversely impacting the profitability and development of the Group. For biosimilars, the rollout of centralized procurement and other policies presents both challenges and opportunities to enterprises. While certain biosimilars may expand their market share through centralized procurement, they may also be subject to continuous price reduction pressure. Although the official implementation of the segmented production policy for biological products provides regulatory flexibility for biopharmaceutical companies to optimize resource allocation and reduce production costs, it imposes high entry barriers on contract manufacturers, presents significant challenges in cross-provincial regulatory coordination, and introduces risks regarding production continuity that cannot be overlooked.

With the deepening reform of the medical system, the National Healthcare Security Administration has initiated a comprehensive governance of drug and consumable prices, and extended it to retail terminals. Meanwhile, it increased the reform efforts in healthcare payment based on Diagnosis Related Groups (DRG) and Diagnosis Intervention Packet (DIP), aiming to further optimize and reshape medical practices.

In addition, the competition for generic drugs in the overseas markets, mainly in the U.S., has been intense and price pressure has further increased. At the same time, the drug regulatory agencies are imposing increasingly stringent requirements on production quality. These factors constitute unavoidable risks during the deepening of internationalization. In emerging markets such as Africa, Southeast Asia, Latin America and Middle East, more generic drug companies have joined the competition, resulting in intensified price pressure on government tenders, as well as increasing risks of competition.

In this regard, the Group will continuously track the changes in development trend of the industry and policy, insist on innovative R&D, enrich product pipelines, optimize product structure, and enhance the R&D efficiency. At the same time, the Group will continuously enhance the benefits from economies of scale in production and operations, and proactively improve quality and increase productivity. In terms of marketing, the Group will increase efforts in market development and enhance the product competitiveness, so as to further expand market coverage.

(III) ***Business and operating risks***

1. *R&D risks of drugs*

Drugs must undergo processes ranging from preclinical studies, clinical trials, application for registration and approval for production from the R&D stage to marketing stage, and R&D of drug is characterized by large investment, long cycles, high risks, etc. and is subject to various unpredictable factors. In addition, if the R&D of drugs does not match future market demand, or if the sales of the drugs are not sufficient due to intensified competition and other factors, the recovery of the initial investment and the realization of economic benefits may be affected, which will in turn adversely affect the profitability and development of the Group.

In this regard, the Group will continue to strengthen its project initiation and early research capabilities, establish a lean R&D concept and process, scientifically employ Go/No-go decisions, and facilitate the continuous improvement of R&D efficiency and output with an effective reward and punishment mechanism. In addition, the Group will further strengthen its capabilities in clinical registration and two-way licensing, and accelerate the approval and launch of innovative products by developing or introducing product pipelines with high clinical value and strong innovative attributes. At the same time, leveraging models such as industry-academia-research collaboration, industrial investment and fund incubation, the Group will actively cultivate and build competitive product pipelines.

2. *Quality control risks of products/services*

Drugs, medical devices and diagnostic products are special commodities, and the society always pays a great deal of attention to their quality. In this regard, the Group has been continuously increasing its construction of the quality management system and investment in technological upgrading. The technology and equipment standards as well as management ability of each subsidiary have been significantly improved. However, due to the long chain and many production stages for pharmaceutical products, quality issues may arise due to raw materials, production, transportation, use and other matters. Meanwhile, the Group has formulated corresponding management measures and established management bodies to ensure that the procurement, inventory, preparation, and sales of pharmaceuticals, medical devices and diagnostic products comply with GMP and GSP and relevant requirements, so as to operate in accordance with the laws. However, there may still be the possibility that the relevant operating entities will be punished for failing to strictly abide by relevant laws and regulations due to various reasons such as poor management in the actual course of operation.

The healthcare services business may be subject to risks of medical safety incidents or disputes between doctors and patients, such as complaints and disputes between doctors and patients arising from surgical procedure deviation, clinical misdiagnosis and incidents relating to defects of treatment and diagnostic devices. In the event of serious medical safety incidents, relevant compensation and loss may be incurred by the Group, which may in turn adversely affect the operation results, brand image and market reputation of the Group's healthcare services institutions.

In this regard, the Group will continue to maintain lean operation, focus on quality and risk management throughout the life cycle of its products, practically implement quality and safety control mechanisms and pharmacovigilance mechanisms. For healthcare services, the Group will continue to strengthen the construction of disciplines and quality while pursuing business development.

3. *Safety and environmental risks*

Manufacturing companies are also exposed to safety and environmental risks during the operation process. In the process of production of drugs, medical devices and diagnostic products, due to the hazardous chemicals that may be involved in the APIs, improper operation or inadequate maintenance measures during loading, unloading, handling, storage and use may cause production safety incident. Residue, waste gas, waste liquid and other pollutants produced during the manufacturing of products or provision of healthcare services will be harmful to the surrounding environment if they are not treated properly, which in turn will affect the normal production and operation of the Group. Notwithstanding that the Group has conducted the treatment and discharge of pollutants in accordance with the applicable environmental protection laws and regulations and standards in the places where it operates, as public awareness of environmental protection continues to increase, higher environmental protection standards may be promulgated by the jurisdictions where the Group operates in the future, which could lead to a corresponding increase in the Group's environmental protection expenditures and a further rise in operating costs.

In this regard, the Group will continuously strengthen production safety management, reinforce staff training and implement relevant safety production measures to reasonably control risks. Meanwhile, the Group will attach importance to and fulfill its social responsibility for environmental protection, to ensure the normal operation of environmental protection facilities and ensure compliance with discharge standards.

(IV) ***Management risks***

1. *Risks of internationalization*

Geopolitical uncertainty poses risks to the internationalization of the pharmaceutical and healthcare industry. The Chinese pharmaceutical and healthcare enterprises' international cooperation may be affected by the new geopolitical patterns and policies.

Meanwhile, during the implementation of the international development strategy, the Group may be affected by a complex and volatile international environment. Sudden changes in international geopolitical conflicts and regional market conditions may result in adjustments to tariff rates in certain countries or regions, changes in procurement demand in international public markets, as well as trade protectionism and market access barriers arising from the restructuring of industrial and supply chains. At the same time, with the accelerated expansion of the Group's global sales network and the extension of its business scope to diverse markets, there will be higher requirements on its overall capabilities. If the Group fails to adjust and advance differentiated and refined marketing and commercialization strategies in a timely manner in response to the foregoing changes and new circumstances, or if the corresponding talent reserves and management models fail to keep pace with the needs of international development, the mismatch between internal and external environments may give rise to operating and management risks.

2. *Risks arising from mergers, acquisitions and integration*

The Group may encounter legal, policy and operating risk exposures during the process of mergers, acquisitions and integration. Upon completion of acquisitions, the requirements on the operation and management of the Group will become higher. If mergers and acquisitions could not bring about a synergistic impact, the operating results of the Group may be adversely affected.

In this regard, the Group will continue, in business operation, to improve its technologies and professionalism, and the understanding of regulatory rules and policies of overseas market so as to minimize the potential operational risks.

(V) *Exchange rate fluctuation risks*

With the profound implementation of the Group's internationalization strategies, the business coverage continues to expand, and the proportion of purchases, sales, and mergers and acquisitions denominated in foreign currencies has continued to increase. Changes in exchange rates will affect the value of assets and liabilities denominated in foreign currencies and the value of overseas entities, thereby indirectly leading to volatility in the Group's income or cash flow over a period of time. With the deepening of exchange rate marketization reforms, exchange rate fluctuations between RMB and other convertible currencies have intensified, and the Group may be exposed to exchange rate fluctuation risks during foreign exchange settlements.

In this regard, the Group will keep monitoring fluctuations of the foreign exchange rate, and continuously optimize the structure of domestic and overseas assets, so as to reasonably control foreign exchange exposure and improve the ability to deal with exchange rate fluctuation risks.

(VI) *Force majeure risks*

Severe natural disasters and abrupt public health incidents may harm the properties and personnel of the Group, and may affect the normal production and operation of the Group.

In this regard, the Group will strengthen the analysis and prediction of force majeure risks, and continuously improve the emergency management system, so as to try to reduce the adverse impact that force majeure incidents may bring to operations.

VII. Other Events

(I) *Proposed Spin-off Listing of Fosun Adgenvax (a Subsidiary of the Company) on the Main Board of the Hong Kong Stock Exchange*

On 22 January 2026, the Board resolved that, in order to better promote the continuous improvement of corporate governance standards and the robust and sustainable development of subsidiaries with specific industry platform capabilities within the Group thereby maximizing shareholder value, the Company proposed to spin off its subsidiary, Fosun Adgenvax (the Group's vaccine platform enterprise), for a listing on the Main Board of the Hong Kong Stock Exchange.

At the extraordinary general meeting held on 27 February 2026, the Shareholders approved, among other things, the resolutions regarding the proposed spin-off of Fosun Adgenvax and its listing on the Hong Kong Stock Exchange. On 26 June 2026, Fosun Adgenvax has submitted a listing application through its joint sponsors to the Hong Kong Stock Exchange to apply for the listing of, and the permission to deal in, the H shares of Fosun Adgenvax on the Main Board of the Hong Kong Stock Exchange. The initial size of the Proposed Issuance of Fosun Adgenvax shall not exceed 25% of the enlarged total share capital of Fosun Adgenvax immediately after the issuance, and the global coordinator(s) or bookrunner(s) shall be granted an over-allotment option not exceeding 15% of the aforementioned initial issuance size.

As at the date of this announcement, the Proposed Spin-off Listing is subject to, among other things, the filing or approval of the CSRC, the Hong Kong Stock Exchange and other relevant regulatory authorities, the market conditions and other factors, and there is no assurance on the aforesaid filing or approval.

(II) ***Approval from the CSRC for Registration of the Science and Technology Innovation Corporate Bonds***

On 13 February 2026, the CSRC issued the Approval on the Public Issuance of the Science and Technology Innovation Corporate Bonds to the Professional Investors by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (Zheng Jian Xu Ke [2026] No. 298) (the "**Approval**"), approving the application for registration of the Company for the public issuance of the Science and Technology Innovation Corporate Bonds with an aggregate par value not exceeding RMB6 billion to professional investors. The Approval shall be valid within 24 months from the date of the CSRC's approval for registration, and the Company may issue in tranches within the validity period of registration.

As at the date of this announcement, no Science and Technology Innovation Corporate Bonds have been issued pursuant to the Approval.

REPURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES (INCLUDING TREASURY SHARES)

During the Reporting Period, neither the Company nor any of its subsidiaries repurchased, sold or redeemed any of the Company's listed securities, nor disposed of or sold any of its treasury shares.

As at the end of the Reporting Period, the Company held 10,969,000 H Shares as treasury shares which were intended to be used for equity incentive schemes, or to be cancelled; and held 19,906,252 A Shares as treasury shares which were intended to be used for the conversion of convertible bonds to be issued (if any) and/or the implementation of the equity incentive scheme and/or the employee share ownership scheme, or to be cancelled.

COMPLIANCE WITH THE CG CODE

The corporate governance practices adopted by the Company are based on the principles and Code Provisions under the CG Code contained in Appendix C1 to the Hong Kong Listing Rules.

As a company whose shares are listed on the Hong Kong Stock Exchange and the Shanghai Stock Exchange, the Company has remained in compliance with relevant laws and regulations, the Hong Kong Listing Rules, the Shanghai Listing Rules and the Articles of Association. The Company is committed to continuously improving its corporate governance structure, optimizing its internal management and control and its business operation in order to improve corporate governance.

The Board believes that high corporate governance standards are essential in safeguarding the interests of Shareholders, enhancing corporate value, transparency and accountability, as well as formulating corporate business strategy and policy outline.

The Board is of the view that during the Reporting Period, the Company has complied with all the applicable Code Provisions as set out in the CG Code.

MODEL CODE AND WRITTEN GUIDANCE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code regarding securities transactions by Directors as set out in Appendix C3 to the Hong Kong Listing Rules and formulated the Written Guidance as its codes of conduct regarding securities transactions. Having made specific enquiry of the Directors, all the Directors have confirmed that they have complied with the standards for securities transactions by directors as set out in the Model Code and the Written Guidance throughout the Reporting Period.

REVIEW OF INTERIM RESULTS BY THE AUDIT COMMITTEE

The Group's unaudited interim results for the six months ended 30 June 2026 have been reviewed by the Audit Committee of the Company.

INTERIM DIVIDEND

The Board does not recommend the distribution of interim dividend for the Reporting Period.

PUBLICATION OF INTERIM RESULTS AND 2026 INTERIM REPORT

This announcement is published on the websites of the Company (https://www.fosunpharma.com) and the Hong Kong Stock Exchange (https://www.hkexnews.hk). The 2026 Interim Report will be dispatched to the Shareholders and will be made available on the websites of the Company and the Hong Kong Stock Exchange as and when appropriate.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following terms shall have the meanings set out below.

"A Share(s)"	domestic share(s) of the Company with a nominal value of RMB1.00 each, which are listed on the Shanghai Stock Exchange and traded in RMB
"Abbott"	Abbott Products Operations AG., a company incorporated in Switzerland
"ADC"	antibody-drug conjugate
"AI"	artificial intelligence
"API"	active pharmaceutical ingredient
"Articles of Association"	the articles of association of the Company
"Board"	the board of Directors of the Company
"Breas"	Breas Medical Holdings AB, a company incorporated in Sweden, and a subsidiary of the Company
"BSE"	BSE Limited
"Carelife Pharma"	Chongqing Carelife Pharmaceutical Co., Ltd.* (重慶凱林製藥有限公司), a subsidiary of the Company
"CG Code"	the Corporate Governance Code contained in Appendix C1 to the Hong Kong Listing Rules

"Chinese mainland"	Chinese mainland, for the purpose of this announcement, excluding Hong Kong, Macau and Taiwan region
"Chongqing Shinrong Plastic Surgery Hospital"	Chongqing Shinrong Plastic Surgery Hospital Co., Ltd.* (重慶星榮整形外科醫院有限責任公司), a subsidiary of the Company
"CMC"	chemical manufacturing and control
"Code Provisions"	code provisions under the CG Code
"Company"	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司), a joint stock company established in the PRC with limited liability, whose H Shares and A Shares are listed and traded on the Main Board of the Hong Kong Stock Exchange and the Shanghai Stock Exchange, respectively
"CSRC"	China Securities Regulatory Commission (中國證券監督管理委員會)
"CVRM"	cardiovascular, renal and metabolism
"Director(s)"	director(s) of the Company
"EC"	European Commission
"Eisai"	Eisai Co., Ltd., a company incorporated in Japan
"EU"	European Union
"Foshan Fosun Chancheng Hospital"	Foshan Fosun Chancheng Hospital Limited* (佛山復星禪誠醫院有限公司), a subsidiary of the Company
"Fosun Adgenvax"	Fosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd.*(復星安特金(成都)生物製藥股份有限公司, formerly known as "復星安特金(成都)生物製藥有限公司"), a subsidiary of the Company
"Fosun Health"	Shanghai Fosun Health Technology (Group) Co., Ltd.* (上海復星健康科技(集團)有限公司), a subsidiary of the Company
"Fosun Insightec"	Fosun-Insightec Medical Technologies (Jiangsu Xuzhou) Co., Ltd.* (復星醫視特醫療科技(江蘇徐州)有限責任公司), a subsidiary of the Company

"Fosun Kairos"	Fosun Kairos (Shanghai) Biological Technology Co., Ltd.* (復星凱瑞(上海)生物科技有限公司), a subsidiary of the Company
"Fosun Pharma (Shenzhen)"	Fosun Pharma Industrial Development (Shenzhen) Co., Ltd.* (復星醫藥產業發展(深圳)有限公司), a subsidiary of the Company
"Fosun Pharma (Xuzhou)"	Fosun Pharma (Xuzhou) Company Limited* (復星醫藥(徐州)有限公司), a subsidiary of the Company
"Fosun Wanbang"	Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd.* (復星萬邦(江蘇)醫藥集團有限公司), a subsidiary of the Company
"Gland Pharma"	Gland Pharma Limited, a company incorporated in India and listed on the BSE and the NSE (stock code: GLAND), and a subsidiary of the Company
"GMP"	good manufacture practices
"Green Valley Pharma"	Green Valley (Shanghai) Pharmaceuticals Co., Ltd.* (綠谷(上海)醫藥科技有限公司)
"Group"	the Company and its subsidiaries (or the Company and any one or more of its subsidiaries, as the context may require)
"Guilin Pharma"	Guilin Pharmaceutical Co., Ltd.* (桂林南藥股份有限公司), a subsidiary of the Company
"H Share(s)"	overseas listed foreign share(s) in the ordinary share capital of the Company, with a nominal value of RMB1.00 each, which are listed on the Hong Kong Stock Exchange and traded in Hong Kong dollars
"Hengtai Bio"	Shenzhen Hengtai Biotechnology Co., Ltd.* (深圳衡泰生物科技有限公司), an associate of the Company
"Hepa Thera"	Suzhou Hepa Thera Biotech Co., Ltd. (蘇州星曜坤澤生物醫藥股份有限公司), an associated company of the Company as at the end of the Reporting Period
"Hong Kong Listing Rules"	the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange

"Hong Kong Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"IND"	investigational new drug
"Innovative Drugs"	For the purpose of this announcement, mainly include innovative drugs, biosimilars, improved new drugs and other drugs with high technological barriers formed through technological innovation
"Intuitive Fosun"	Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd.* (直觀復星醫療器械技術(上海)有限公司) and/or Intuitive Surgical-Fosun (Hongkong) Co., Limited, each is an associated company of the Company
"Jianjia Healthcare"	Jianjia Healthcare Investment Management Co., Ltd.* (健嘉醫療投資管理有限公司), a subsidiary of the Company
"Macau"	the Macau Special Administrative Region of the PRC
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Hong Kong Listing Rules
"NDA"	new drug application
"NMPA"	National Medical Products Administration (中國國家藥品監督管理局)
"NSE"	The National Stock Exchange of India Limited
"PRC" or "China"	The People's Republic of China
"Proposed Issuance of Fosun Adgenvax"	the initial public offering of shares and listing on the Main Board of the Hong Kong Stock Exchange of Fosun Adgenvax
"Proposed Spin-off Listing"	the proposed spin-off of Fosun Adgenvax, a subsidiary of the Company, for listing on the Main Board of the Hong Kong Stock Exchange
"R&D"	research and development
"Reporting Period"	the 6-month period from 1 January 2026 to 30 June 2026

"RMB"	Renminbi, the lawful currency of the PRC
"Shandong Erye"	Shandong Erye Pharmaceutical Co., Ltd.* (山東二葉製藥有限公司), a subsidiary of the Company
"Shanghai Henlius"	Shanghai Henlius Biotech, Inc.* (上海復宏漢霖生物技術股份有限公司), a company incorporated in the PRC and listed on the Hong Kong Stock Exchange (stock code: 02696), and a subsidiary of the Company
"Shanghai Listing Rules"	the Rules Governing the Listing of Stocks on the Shanghai Stock Exchange (《上海證券交易所股票上市規則》)
"Shanghai Stock Exchange"	the Shanghai Stock Exchange (上海證券交易所)
"Shareholder(s)"	holder(s) of Shares
"Shares"	ordinary shares in the capital of the Company with a nominal value of RMB1.00 each, comprising A Shares and H Shares
"Sinopharm Industrial"	Sinopharm Industrial Investment Co., Ltd.* (國藥產業投資有限公司), an associated company of the Company
"Sinopharm"	Sinopharm Group Co. Ltd.* (國藥控股股份有限公司), a company incorporated in the PRC and listed on the Hong Kong Stock Exchange (stock code: 01099), a subsidiary of Sinopharm Industrial
"Sisram Medical"	Sisram Medical Ltd, a company incorporated in Israel and listed on the Hong Kong Stock Exchange (stock code: 01696), and a subsidiary of the Company
"Suzhou Erye"	Suzhou Erye Pharmaceutical Co., Ltd.* (蘇州二葉製藥有限公司), a subsidiary of the Company
"SVAX"	AL-TIRYAQ AL-KHALAWI Medical Company, a company incorporated in Kingdom of Saudi Arabia
"U.S." or "United States"	United States of America, its territories and possessions, any state of the United States and the District of Columbia
"WHO PQ"	World Health Organization Prequalification

"Written Guidance"	Written Guidance for Securities Transactions by Directors/Relevant Employees of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (《上海復星醫藥(集團)股份有限公司董事／有關僱員進行證券交易的書面指引》)
"Yao Pharma"	Chongqing Yao Pharmaceutical Company Limited* (重慶藥友製藥有限責任公司), a subsidiary of the Company
"%"	per cent

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
25 August 2026

As at the date of this announcement, the executive Directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive Directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive Directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee Director of the Company is Ms. Yan Jia.

* *For identification purposes only*